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ABSTRACT 
PARTICIPATION OF MOUSE DNA POLYMERASES IOTA, ETA, AND REV1 IN 
TRANSLESION SYNTHESIS OF CARCINOGEN INDUCED DNA ADDUCTS 
AND CARCINOGENESIS 
Chad Aaron Dumstorf 
March 21 , 2007 
Recent advances in undE~rstanding the molecular mechanisms of 
mutagenesis indicate that most mutations are dependent on the activity of 
translesion synthesis DNA polymerases. The impact of reducing the level of 
these polymerases on mutageneslis and carcinogenesis in mouse models is 
poorly defined. Using knock out strategies we were able to remove polymerase 
eta (pol 11), and polymerase iota (pOll) and pol eta/pol iota from the mouse and 
lower REV1 in the mouse lung. This dissertation reports the changes in UV-
induced carcinogenesis and mutagenesis that were observed. 
Mutagenesis data in pol iota. deficient cells clearly indicate pol iota as a 
mutagenic TLS polymerase in UV lesion bypass. Pol iota removal effectively 
lowered the mutational frequency in both pol eta null and wild-type backgrounds. 
v 
Unexpectedly, after Hprt mutant screening, pol eta and pol iota deficient cells 
were found to participate in UV lesion bypass in a strand-specific manner. This 
suggests that not only does bypass of photoproducts occur but occurs in an 
asymmetrical fashion, with preference of polymerases for leading or lagging 
strand. 
To examine the hypothesis that reducing the mutagenic load will reduce 
the incidence of cancer, we examined how pol iota status contributes to 
carcinogenesis. Despite the fact that pol iota was mutagenic in bypass of UV 
induced lesions, its removal accelerated cancer formation in the pol eta null 
background. The mechanisms behind this tumor suppressor function remain 
elusive, but indicate pol iota may have additional cellular roles in conjunction with 
its polymerase activity. 
Examining the hypothesis that reducing the mutagenic load will reduce the 
incidence of cancer, we developed strategies to reduce REV1 in mouse models 
of lung carcinogenesis. Endogenous REV1 mRNA in the lung was effectively 
lowered with the use of gene delivery of REV1 targeting ribozyme. This reduction 
was found to effectively decrease the multiplicity of B[a]P-induced lung tumors. 
This reduction did not affect the size or types of tumors induced suggesting 
inhibition of cancer formation occurred at the initiation step. Collectively, these 
data yield insight into the molecular mechanisms of mutagenesis that induce 
cancer formation. 
VI 
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Genomic stability is central to the survival of cells, both prokaryotic and 
eukaryotic. The loss of such stability is fundamental for evolution and is most 
easily appreciated in single-cell organisms. It is more difficult to understand why 
multicellular organisms have maintained mechanisms that result in alterations in 
the primary sequence of DNA, since such alterations are thought to underlie 
cancer and a wide variety of diseases associated with aging. Never the less, 
these molecular pathways, collectively called DNA damage tolerance, have been 
highly conserved. The chemical stability of DNA has been recognized for 
decades, but the cellular DNA of living organisms is continually subjected to 
many DNA damaging agents, which must be bypassed if the cell is to survive. In 
this context, "bypass" refers to the completion of replication of genomes that 
contain helix-distorting lesions such as those induced by the environmentally 
relevant carcinogens ultraviolet (UV) radiation and benzo[a]pyrene (8[a]P). It is 
now recognized that the principal mechanism underlying mutagenesis is the 
direct replication of DNA that contains non-instructive bases as a result of 
1 
adduction with these carcinogens. These agents, whether exogenous or 
endogenous, damage DNA, induce mutations, and cause cancer. This 
dissertation specifically focuses on the bypass of bulky helix distorting lesions 
induced by the aforementioned agents. This bypass, termed translesion 
synthesis (TLS), is responsible for both error free and mutagenic bypass of these 
lesions. The studies covered, in this dissertation yield new insight into the 
polymerases responsible for inducing mutations after UV and B[a]P exposure 
and how manipulating these polymerases effects cancer formation. 
ULTRAVIOLET LIGHT 
UV light is generally segregated into three varying wavelengths UV-A 
(long wave UV with a -380 to -315nm wavelength), UV-B (medium wave with a 
-315 to -280nm wavelength), and UV-C (short wave UV that ranges less than 
280nm). Absorption of UV light produces two predominant types of DNA 
damage, cyclobutane pyrimidine dimers (CPO) and 6-4 pyrimidine-pyrimidone 
photoproducts (6-4PP). The structure for CPO and 6-4PP are shown in Figure 
1 a-b. Both of these helix-disturbing lesions can be induced by the complete 
spectrum of UV light (-380nm-1 OOnm), albeit to varying extents 1. 
The production of CPO's and 6-4PP's from UV-A wavelength absorption is 
considered relatively minor. Despite low levels of photoproduct formation this 
wavelength probably contributes to carcinogenesis. It has been postulated that 
the formation of oxidative free radicals, rather than photoproduct production, is 
the most damaging aspect of UV-A exposure2 . Longer wavelengths such as 
2 
those in the UV-A and UV-B region are long enough to pass through the ozone 
and reach the earth's surface. Since UV-B also passes to the earths surface and 
is energetic enough to form considerable amounts of CPO and 6-4PP 
photoproducts, it is considered the most biologically significant source of UV 
damage3 . The more energetic short-wave UV-C radiation is the most damaging 
to DNA, but generally does not penetrate the ozone thus preventing it from 
reaching the Earth's surface. Nevertheless, the dosimetry and resulting adduct 
load following UV-C exposure has been well-established after over 40 years of 
use in DNA repair and mutagenesis studies. Therefore, UV-C is commonly used 
in the laboratory to induce DNA photoproducts for biological studies4 . UV-C may 
also be produced in occupational settings, such as welding, and may possibly 
contribute to skin cancer in exposed populations5 . 
CPO form as a result of covalent linkages between adjacent pyrimidine 
bases in the form of a four carbon (cyclobutane) ring, as illustrated in Figure 1 a. 
CPO may occur between any two pyrimidines (i.e. 5' T <> T, 5' T <>C, 5' C<> T, or 
5' C<>C)6. The occurrence of the type of pyrimidine dimer formed is sequence 
dependent with 5' T <> T being the most common CPO and 5' C<>C the least7 . 
Unlike CPO, 6-4PP occur primarily between 5' T <>C, 5' C<>C, and less 
frequently at 5' T <> T with little formation between 5' C<> T8. This linkage, as 
illustrated in Figure 1 b, is a covalent bond between the C6 position of the 5' 
pyrimidine and the C4 position of the 3' pyrimidine. 
The frequency of photoproduct formation is greater for both CPO and 6-
4PP at shorter wavelengths. Though it is possible that the ratio of CPO to 6-4PP 
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production varies with wavelength, it is generally considered that regardless of 
wavelength, CPO occur 4 - 5 times more frequently than 6-4 photoproducts9,1O. 
Because the proportion and type of CPO and 6-4PP are relatively stable for UV-B 
or UV-C, the decision for which wavelength to use for biological experimentation 
is subject to the nature of a particular experiment. Because of this, the 
experiments covered in this dissertation involve UV irradiation of both cells and 
mice at different wavelengths. UV-C with a sharp 254 nm emission is used for 









Figure 1. Major UV light induced photoproducts 1 a) Absorption of ultraviolet 
(UV) light produces two predominant types of UV light induced adducts. a) T <> T 




Benzo[a]pyrene (B[a]P) is a natural byproduct and is ubiquitously 
distributed throughout the environment through the combustion of organic matter. 
B[a]P is readily absorbed via the gastrointestinal (GI) tract, lung and skin. The 
compound is activated and detoxified primarily in the liver although other organs 
such as the lung, skin, GI, and placenta can contribute significantly to these 
processes11 -13. B[a]P and many other polycyclic aromatic hydrocarbons (PAH) 
are activated to intermediates that covalently bind to DNA as a result of 
endogenous cytochrome P450 metabolism 14. B[a]P in its unmodified form is a 
hydrophobic planar shaped molecule (Figure 2a). 
In order for B[a]P to bind DNA it must undergo cytochrome P450 
enzymatic reactions that create a variety of phenols, dihydrodiols, and 
electrophilic epoxides. While the principle mutagen is debated, it is widely 
accepted that (±) anti diol-epoxides (BPDE) (Figure 2b) react at N2-dG in DNA 
(Figure 2c) to give four stereoisomers. More specifically the (+)-anti-BPDE reacts 
with DNA via trans- and cis- configurations to give [+ta]- and [+ca]-B[a]P-W-dG. 
Similarly (-)-anti-BPDE gives [-ta]- and [-ca]-B[a]P-W-dG adducts (Figure 2d) 15. 
While all four of the steroisomers can cause mutations, principally G-T 
transversions, the [+ta]-B[a]P-W-dG produces the dominant adduct16 . 
B[a]P is given to animals used in this dissertation to primarily induce 
murine lung tumors. Activation to its carcinogenic potential is therefore based on 
the animals' own metabolic pathways. In contrast, the human fibroblasts used in 
the cell culture assays referenced throughout this dissertation lack the capacity 
6 
for B[a]P activation. These cell culture based assays therefore require the use of 



















I +t'a I-Blal P-N.2-dG 
Figure 2. IIIUlstrations of the polycyclic aromatic hydrocarbon 
benzo[a]pyren,e (8[a]P), its electrophilic metabolite, and major DNA 
adduct. 2a) B[a]P 2b) one known metabolite benzo[a]pyrene-7,8-diol-
9,10-epoxide (BPDE), and 2c) DNA adduct formed on the N2 position of 
guanine. 2d) Structures of the four stereoisomers of l\f-dG adducts: [+ta]-, 
[+ca]-, [- ta]- and [- ca]-B[a]P-I\f-dG. 
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POLYMERASE STALLING 
Environmental DNA-damaging agents such as UV-light and B[a]P can 
produce damage to nucleotides (lesions) which can block transcription and 
replication complexes. Inhibition of such fundamental DNA transactions may 
have detrimental results, such as the induction of mutations or cell death. 
Therefore, cells have evolved efficient mechanisms for the recognition of helix-
distorting lesions. Ar~Juably the most versatile system for recognizing and 
removing such lesions, including those induced by UV or B[a]P, is nucleotide 
excision repair. Lesions on a base in the transcribed strand of an active gene 
have a high propensity to block the RNA polymerase complex. Such polymerase 
stalling induces cell-cycle arrest, and possibly apoptosis, in a p53-dependent 
manner17. In addition, the stalled complex acts as damage-recognition sensor to 
signal the excision repair apparatus via the Cockaynes syndrome A and B 
(CSA/B) proteins. CSA/B signals the basal transcription complex TFIIH to the 
stalled polymerase, by mechanisms that are not fully understood. However, the 
RNA polymerase is generally considered to "back up" in order to expose the 
lesion. The helicase activity inherent in TFIIH unwinds the DNA, allowing the 
scaffolding protein XPA to gain access to the lesion and RPA to coat single-
strand DNA. Subsequent steps include endonuclease activity by XPG 3' to the 
lesion and XPF-ERCC1 5' to the lesion in an ordered series of reactions. This 
results in a 26-29 base oligonucleotide gap containing the lesion. The gap is 
filled in by the replicative DNA polymerase complex and sealed with a ligase. 




Lesions in non-transcribed regions are repaired by global genomic pathways, 
which differ from transcription-coupled repair (TCR) only in the manner of lesion 
recognition. It is known that CPO are initially recognized by XPE and then this 
complex attracts the XPC-HHR23B complex. Lesions that distort the helix to a 
greater extent, such as 6-4 PP and BPDE-induced adducts, are directly 
recognized by XPC-HHR23B. The subsequent steps proceed as in TCR. 
If the cell enters S-phase with residual (unrepaired) DNA damage, which 
can occur if the damage is induced close to the onset of S-phase or if the cells 
cannot remove the damage as a result of DNA repair defects, the DNA 
polymerase may be bllocked 19 . Current data indicate that cells may use at least 
two complementary pathways to continue replication across the damage. These 
pathways are collectilvely called "damage tolerance", since the damage is 
tolerated rather than mmoved. These were first identified in the budding yeast S. 
cere visia e, and are within the RAD6 epistasis group. Recent data have begun to 
elucidate the molecular mechanisms underlying this pathway, and indicate a 
remarkable conservation of these mechanisms in higher eukaryotes. One 
pathway, called "damage avoidance", copies undamaged DNA with the same 
sequence as the original template. This can occur by using the sister chromatid 
sequence or by "copy-choice" template switching in which the nascent strand 
templated by the undamaged strand is used as the template. Both mechanisms 
are recombinational in nature are considered to be error-free. An alternative 
mechanism, termed translesion synthesis (TLS) uses accessory polymerases in 
lieu of normal replication polymerases to bypass the damage. Unlike "damage 
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avoidance", these polymerases switch places with normal replication machinery 
and continue to use the damaged strand as a template. Because the damage 
remains, the bypass may result in error free or error prone incorporation of 
nucleotides across thB lesion. TLS is summarized at the end of this chapter 
(Figure 3). 
The RAD6-dependant damage tolerance pathway is central to both of 
these "damage tolerance" pathways. Though the exact mechanism cells use to 
decide whether TLS or "damage avoidance" is employed remains controversial, 
there are some well-characterized components. The RAD6 gene encodes the 
ubiquitin conjugating Bnzyme (Ubc or E2) that is required along with RAD18 
(UBL or E3) for dama<ge tolerance to occu~o. Cysteine-88, located in the RAD6 
enzyme active site, is required for its ubiquitin conjugating activitl1. Upon 
replication fork stalling, the RAD6-RAD18 complex binds to the DNA through a 
chromatin associated RING finger motif22. This complex mono-ubiquitinates the 
proliferating nuclear cBII antigen (PCNA) at lysine-164 (K164) which signals the 
recruitment of a variety of accessory DNA pOlymerases23. 
Current data indicate that the "damage avoidance" pathway also requires 
the further poly-ubiquitination of the conjugate at lysine-63 (K63)24. This multi-
ubiquitination allows the recruitment of MMS2, UBC13, and RAD5 which are 
required for "damage avoidance" to OCCU~3. With the stalling of replication 
machinery and the poly-ubiquitination of PCNA there are at least two 
mechanisms for the "damage avoidance" pathway. While both mechanisms 
result in error free replication, the differences lie in where the information for non-
11 
damaged sequence tHmplate arises. The first proposed mechanism uses an 
allelic copy as a template. The other mechanism employs the use of the newly 
synthesized sister strand25. Regardless of the mechanism, data indicate that loss 
of MMS2 ubiquitin conjugating enzyme-like protein (required for the poly-ubiquitin 
chain) in S. cervisiae increases the mutagenic effect of UV light and spontaneous 
mutations. Although much more controversial in higher eukaryotic cells, such 
cells have homologs to the polyubiquitination machinery, and knockdown of 
MMS2 results in less recombination and more mutants induced by UV. Available 
data support a role for polyubiquitination in recombination-mediated damage 
avoidance26-28. 
Current models hypothesize that mono- or polyubiquitination of PCNA is 
the molecular switch that determines whether the cell will undergo damage 
avoidance (polyubiquitination) or TLS (monoubiquitination)29. This process is 
further complicated by studies that indicate PCNA may also be conjugated by 
small ubiquitin-like modifier (SUMO) USCg at K16430. While poorly understood, 
data indicate that the attachment of SUMO (sumoylation) to PCNA is an event 
that occurs to recruit the helicase Srs2 to the site of damage31 . This recruitment 
effectively prevents recombination during S phase and apparently shifts the cell 
away from damage avoidance and into TLS32,33. While this mechanism likely 
plays an extremely important role in damage tolerance, the purpose of 
sumoylation is still poorly defined. In any case, these PCNA modifications have 
been shown to affect DNA damage resistance and support the notion that the 
12 
alternative modes of rnodification of PCNA act as molecular switches to enable 
alternative functions in lesion bypass. 
The second option employed by cells is termed trans lesion synthesis 
(TLS). TLS also occurs at stalled replication forks, but unlike "damage 
avoidance" occurs when PCNA is either monoubiquitinated or as recent data 
indicates perhaps sumoylated23 . TLS enables the cell to avoid apoptosis through 
the recruitment of specialized DNA polymerases. These polymerases generally 
have less stringent base pairing requirements and are able to accommodate the 
lesion into their active site. These low fidelity polymerases are well adapted to 
replicate across helix distorting lesion in such a way that the outcome may result 
in mutagenic or error free bypass of lesion. While the exact sequence of events 
that occurs in TLS is still being elucidated, much of what is currently known is 
through individual polymerase and protein analysis. Three major TLS proteins 
are the subject matter of the studies covered in this dissertation and a general 
discussion of their history and significance in TLS is given in the following 
section. 
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Y-FAMIL Y POL YMERASES 
Y -family polymerases are a functionally diverse group of DNA 
polymerases that are characterized by their low fidelity of replication and ability to 
efficiently bypass a variety of helix distorting DNA lesions. Originally named the 
UmuC/DinB/Rev1/Rad30 super-family, these polymerases share similar amino 
acid sequence homology to themselves and little homology to other polymerase 
families34 . These polymerases lack proofreading capabilities and appear to 
exhibit great diversity among themselves in lesion specificity, rate of nucleotide 
incorporation, and extension of mismatched primer-termini. Data suggest many 
of these are able to participate in lesion bypass past adducts that typically 
impede normal replication machinery but the extent to which it occurs is poorly 
understood35 . These polymerases have traditionally been labeled error-prone 
translesion polymerases, most likely due to their low fidelity characteristics, but 
may also function in an error-free manner across these lesions36,37. 
TLS is generally performed by one or another of the Y-family polymerases 
with one extremely important exception. DNA polymerase zeta (pol zeta/ pol l;), 
which is a member of the B-family of polymerases, together with the replicative 
polymerases a, 0, and £, is required for TLS to occur. Pol zeta is composed of 
two subunits encoded by the REV3 and REV7 genes38 . REV3 is the catalytic 
subunit of pol zeta and results in embryonic lethality when abolished in mice39,40. 
Despite the embryonic lethality that occurs with REV3 knockout strategies, 
insights into pol zeta function in higher eukaryotes have been gained using 
antisense-mediated strategies in cell culture and in mice. Mice that express 
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antisense to mREV3 endogenous RNA transcripts, which do not have completely 
abolished REV3 protein, are viable, These mice also have a decreased 
frequency and highly aberrant spectrum of UV-induced mutations at the 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) locus indicating a 
fundamental role for pol zeta in TLS39 , Additionally, these knockdown mice have 
reduced levels of B cells and impaired development of high-affinity memory B 
cells perhaps suggesting an additional function in somatic hypermutation41 ,42, Pol 
zeta is also capable, unlike other polymerases implicated in TLS, to efficiently 
extend past DNA damaged induced lesions43, Since most Y-family polymerases 
inefficiently incorporate nucleotides after lesion bypass, pol zeta has been 
proposed to be responsible for finishing the bypass before normal replication 
resumes, Additionally, human REV3 (hREV3) has been shown to be essential for 
error prone translesion synthesis past UV or BPDE-induced lesions in human 
fibroblasts44, These data collectively indicate a primary function for pol zeta in 
extension past the lesion once the damage is bypassed45 , 
Y -family TLS polymerases REV1 and pol eta are homologous in yeast and 
higher eukaryotes, In contrast, the latter cells have two additional, distinct 
homologs termed pol iota and pol kappa46 , These polymerases are capable of 
accepting various DNA lesions into their active sites and are able to replicate 
across helix distorting lesions that would normally impede replication machinery, 
However, the cellular roles of each member of this superfamily are unknown34 , 
The studies in this dissertation were designed to examine the relative importance 
of these enzymes in the bypass of structurally diverse lesions in the context of 
15 
intact cells and to determine if members of this family are potential targets for 
cancer chemoprevention. 
POLYMERASE ETA 
Polymerase eta (pol eta/ pol ll) is the best characterized enzyme in the Y 
family and absence of the enzyme results in the skin cancer-prone xeroderma 
pigmentosum variant (XP-V) syndrome. Xeroderma pigmentosum (XP) patients 
are noted for the predisposition to sunlight induced skin cancer. XP is subdivided 
into seven subclasses called complHmentation groups, labeled XP-A through XP-
G .. Theses complementation groups (XP-A to XP-G) are known to exhibit a 
deficiency in the rate of excision repair of UV induced DNA damage, which 
contributes to their cancer predisposition. In addition to these seven 
complementation groups, there is one additional group termed XP-V. These 
patients are considered variant dUH to exhibiting similar clinical symptoms and 
cancer predisposition, but unlike thH other complementation groups have normal 
excision repair after DNA damage from UV light47. Human fibroblasts derived 
from the XP-V patients have a moderately increased sensitivity to the cytotoxic 
effects of UV-light but are extremely hypermutable when exposed to UV, despite 
having normal NER47. These CEdis also have a higher rate of transformation to 
anchorage independence after UV48. 
It had been suspected for some time that the XP-V gene encoded a 
protein that was involved in error-prone DNA replication, but the defective gene 
product was not identified as a DNA polymerase until 199936 . These studies used 
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primer extension assays past a site-specific CPO, and isolated a homolog of the 
yeast Rad30 protein in XP-V cE311 extracts49 that was found to be capable of 
bypassing T-T CPO. In addition, eiglht mutations were found in the hRad30 gene 
in human XP-V cell lines, with seven resulting in severely truncated hRad30 
protein5o . Earlier studies also indicate that XP-V cells are less likely to 
incorporate dAMP or dGMP opposite the pyrimidine photoproduct, and 
preferentially induce unusual CG to AT mutations arising from photoproducts in 
the leading strand template51 ,52. Coillectively these studies support the conclusion 
that pol eta is a tumor suppressor, and the absence of the enzyme results in the 
cancer-prone XP-V syndrome. 
The mechanism of tumor suppression by pol eta appears to be its 
remarkable ability to efficiently incorporate AA across TT dimers with nearly the 
same efficiency and processivity as undamaged template53,54. This is presumed 
to result from accommodation of tlhe photoproduct within its open active site. 
However, pol eta is unable to successfully complete bypass of 6-4PP 
photoproducts, although it can prefEHentially incorporate a G opposite the 3'T of 
the adduct55 . Thus pol eta has evolved to specifically bypass the most common 
lesion induced by UV, namely CPO between adjacent thymidine bases. It is 
presumed that the hypermutability of XP-V cells after exposure to UV results 
from the mutagenic bypass of the lesion by another, error-prone polymerase. 
The question of the specificity of pol eta with respect to UV is 
controversial. Early studies indicated that XP-V cells were not abnormally 
sensitive to BPOE56, but recent data indicate that mutagenic responses to BPOE 
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are reduced in such cells (BurkE~ and McGregor, unpublished). In primer 
extension assays using purified Emzyme, pol eta is error prone when it bypasses 
a BPDE adduct, preferentially insE~rting dAMP across from the adduct. Such 
insertion would be consistent with the observed GC to T A transversions induced 
by BPDE in cells. In addition to CPD bypass, pol eta efficiently bypasses DNA 
damage57-60 from other adducts. Pol eta has been shown to be able to efficiently 
and accurately replicate through 8-oxoguanine (8-oxoG) lesions by inserting a C 
across from the lesion61 . In vitro, such bypass has the same efficiency as that of 
an undamaged G. However, the relevance of these in vitro studies with purified 
enzyme to intact cells is not resolved. 
The evidence implicating pol eta in the error-free TLS is convincing. 
However, the polymerase or polymerases responsible for UV induced mutations 
in XP-V, and by extension in wild-type cells, are unknown. The increased UV-
induced mutagenesis associated with pol eta deficiency indicates that mutagenic 
bypass of UV photoproducts can be catalyzed by other polymerases. Two Y-
family polymerases have been hypothesized to assume lesion bypass in the 
absence of pol eta. One candidatH is pol zeta, which can bypass a thymine-
thymine dimer in vitro62 , and is required for a large proportion of UV mutagenesis 
in both yeast and mammalian cells. Another candidate is pol iota, which 
physically interacts with pol eta and co-localizes with pol eta at replication foci 
following UV irradiation63. Chapter " examines the hypothesis that pol iota is 




Polymerase iota (pol t) is a Y -family polymerase encoded by the RAD30B 
gene. Its shares homology to pol eta and is known to exist in many species 
including drosophila and mammals, but it is not found in yeast. Pol iota has been 
shown to have varying roles in species dependent in vitro lesion bypass assays. 
Specifically, in vitro evidence suggE~StS that pol iota bypasses cis-syn TT dimers 
in drosophilia but the human enzyme does so with lower efficiencl4,65. Authors 
have speculated that pol iota arosl3 as a duplication of pol eta, but may have 
evolved more specialized properties in evolutionary time frames. 
There have been conflicting reports on the exact abilities of pol iota to 
bypass various lesions in vitro. For instance, some early studies indicate pol iota 
as having limited insertion across CPO, while others report complete lesion 
bypass66 . It is possible these differences may be a result of pol iota's fidelity 
being template and sequence dependent66 . While numerous primer extension 
assays indicate pol iota does perform misinsertion of nucleotides across various 
lesions67 , there still is no concrete evidence suggesting a cellular role in TLS. 
Two hypotheses have been promulgated regarding the outcome of putative 
UV photoproduct bypass by pol iota. One suggests that bypass should be 
mutagenic due to pol iota-catalyzed misinsertion of nucleotides opposite 
photoproducts67,68. Pol iota is rHnowned for high rates of misinsertion of 
nucleotides opposite template pyrimidines during DNA synthesis in vitro64 ,66,69. 
However, a study of UV-induced mutagenesis in a shuttle vector replicated in 
cultured 293T cells, in which pol iota expression was decreased using siRNA 
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concluded that pol iota has no significant role in UV lesion bypass and 
mutagenesis57 . A second hypothesis is that pol iota bypass could be 
antimutagenic for UV-induced C to T transition mutations. This derives from an 
undisputed pol iota preference for inserting dGMP opposite template T70 leading 
to the suggestion that synthesis by pol iota could be antimutagenic via insertion 
of dGMP opposite lesions resulting from deamination of cystosine. Indeed, 
cytosines in dipyrimidine photoproducts readily deaminate71 and pol iota readily 
inserts dGMP opposite template uracil in cyclobutane pyrimidine dimmers 
(CPD)72. 
Additionally, it has been hypothesized that polymerase iota may serve 
other biological roles outside of TL.S. Its pattern of nucleotide misincorporation 
resembles that which occurs in somatic hypermutation69 . Studies in pol iota-
deficient mice however show normal immunoglobulin hypermutation though this 
could be attributed to other low fidelity polymerases assuming its role when 
absenf3. Pol iota has also been suggested to participate in a specialized form of 
base excision repair (BER) in vivo. This hypothesis is supported largely because 
it possesses a unique 5'- deoxyribose phosphate lyase activity and is catalytically 
more active in gap filling than some types of primer extension7o,74. 
Pol iota has been implicated in tumor suppression. The mouse Pol iota 
gene is on chromosome 18 and within the Par2 (pulmonary adenoma resistance 
2) locus that is a major determinant of susceptibility to urethane-induced 
pulmonary adenomas. Interestingly" two strains of mice with differing lung tumor 
susceptibility differ in Pol iota gene status by 25 nucleotides and 10 amino acids, 
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and the two enzymes have altered substrate specificity, suggesting that pol iota 
is a modifier of lung tumorigenesis75 . More recently, the defective Pol iota allele 
in the 129X1/Sv mouse strain that contains the nonsense mutation in the coding 
sequence has been associated with susceptibility to urethane-induced lung 
tumors76 . These data do not indicate whether the tumor suppressor activity is 
related to the polymerase function or to a separate function that is not currently 
identified. A precedent exists for the latter possibility in the case of REV1, the 
polymerase activity of which is dispensable for and distinct from its role in 
mutagenesis. 
The function of pol iota in a cellular context has remained extremely 
controversial. The experiments described in Chapter II were designed to examine 
our hypothesis that pol iota is involved in the mutagenic bypass of UV 
photoproducts in cells. Additionally, these studies explore the possibility that TLS 
is accomplished by multiple polymerases that act preferentially to bypass 
photoproducts on the leading or lagging strand template. Finally, these studies 
are also used to determine pol iota participation in UV induced skin cancer in 
both pol eta-proficient and pol eta-deficient mice. 
21 
REV1 
It is apparent that virtually all mutations induced by bulky DNA adducts are 
dependent on the activity of DNA polymerase zeta acting in concert with another 
DNA polymerase encoded by the REV1 gene77 , which encodes the REV1 DNA 
polymerase, Together, these proteins are required for the generation of 95% to 
98% of UV-induced base pair substitutions in yeaseS,79, In yeast the protein is 
required for mutagenic TLS past adducts induced in the DNA by a variety of 
mutagensSO-S3 , In vitro studies of the purified protein derived from yeast and 
human sources indicate that REV1 is a deoxycytidyl transferase and incorporates 
dCMP across from a non instructive abasic siteS4 , Further studies indicated that 
REV1 is also capable of incorporating C across from a template dG, dT, dA, and 
dC with preferential insertion across from dGS5 , REV1 uses a unique mechanism 
to accomplish this insertion by allowing the incoming dCTP to pair with an 
arginine in the active site rather than the template baseso, 
Despite this intriguing mechanism, the catalytic activity of REV1 appears 
to be dispensable for TLS, It has been known for some time that the yeast rev1-1 
mutant results from a mutation in REV1 that abolishes the dCMP transferaase 
catalytic activity, Nevertheless, this mutant is proficient for UV mutagenesis, 
These data support the conclusion that REV1 plays a structural role in TLS that 
is distinct from its catalytic activitl3 , Indeed, REV1 has an N-terminal BRCT 
region and a C-terminal "interacting domain" that have variously been implicated 
in protein-protein interactions and in mutagenesiss6-s9, REV1 has been shown to 
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physically interact with the Pol zeta subunit REV? and with the other members of 
the Y _famill5,90-92 through a -100 amino acid C-terminal region in REV1 that 
binds these TLS polymerases. Activity of these polymerases while bound to 
REV1 was normal, as determined by in vitro primer extensions assays93. These 
interactions, including the association of REV1 with replication foci, may be 
mediated by ubiquitin. It has been hypothesized that the ubiquitination of PCNA 
is a molecular switch that facilitates TLS94. REV1 contains ubiquitin-binding 
motifs (UBMs) located at the C terminus of the protein and these motifs have 
been shown to be required for association of REV1 with replication foci 95. These 
data are consistent with current models that REV1 serves as a scaffolding 
protein to tether error-prone polymerases to the site of stalled DNA replication 
forks96 . Whatever the mechanism, data strongly implicate REV1 in mutagenic 
TLS9Y. What remains completely unknown and untested is the role REV1 has in 
carcinogensis. Although the somatic mutation hypothesis of cancer would 
predict that inhibition of the involvement of REV1 in mutagenic bypass would 
lower the incidence of cancer after DNA damage, the actual consequences are 












Figure 3. Translesion synthesis. After DNA damage, polymerase 0 stalls on 
the DNA lesion (not illustrated). Current data indicate that RAD6/ RAD18 
monoubiquitinate PCNA which signals the recruitment of polymerase 11, I, K, and 
REV1. These polymerases insert nucleotides directly across from the lesion, 
most likely in a lesion or sequence dependant fashion. Polymerase ~ then, in a 
semi-processive manner, extends the mispair. This forms a template-primer that 
is fully extendable by polymerase 0 to continue replication98 . 
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CHAPTER II 
PARTICIPATION OF MOUSE DNA POLYMERASE; IOTA IN STRAND-BIASED 
MUTAGENIC BYPASS OF UV PHOTOPRODUCTS AND SUPPRESSION OF 
SKIN CANCER 
SUMMARY 
As indicated earlier, DNA polymerase iota is a conserved Y family enzyme 
that is able to bypass replication-blocking lesions in vitro. However, its role in 
TLS in intact cells is unknown and remains highly controversial. We hypothesized 
that this enzyme is responsible for mutagenic bypass of photoproducts, and that 
this activity is responsible for the extreme hypermutability of cells that lack pol 
eta. To test this, we compared UV-induced mutagenesis in primary fibroblasts 
derived from wild-type mice to mice lacking functional pol iota, pol eta, or both. A 
deficiency in mouse DNA polymerase eta greatly enhanced UV-induced Hprt 
mutant frequencies. This enhanced UV-induced mutagenesis was strongly 
diminished in cells deficient in pol iota. Pol iota deficiency also reduced UV 
induced mutagenesis in wild-type cells. These data conclusively indicate that pol 
iota participates in the bypass of UV photoproducts in cells. Sequence analysis of 
Hprt mutants derived from each of the four genotypes indicated that the lack of 
25 
DNA polymerase eta resulted in a dramatic increase in mutations that were 
targeted by putative photoproducts in the leading strand template. Further, these 
mutations were principally CG to AT transversions. This spectrum completely 
recapitulates that found in human XPV cells. The lack of pol iota did not alter the 
kinds of mutations in either the wild-type or pol eta-deficient background, but 
there was a highly significant reduction in mutations that were targeted by 
putative photoproducts in the lagging strand template. These data support the 
hypothesis that pol eta is specialized for the error-free bypass of photoproducts 
on the leading strand template. In the absence of this enzyme, these 
photoproducts are bypassed by pol iota in a mutagenic fashion. Further, pol iota 
is specialized for error-prone bypass of photoproducts in the leading strand 
template. The reduced frequency of UV-induced mutants in cells lacking pol iota 
would predict that these mice would have a reduced incidence of UV-induced 
skin cancer. We UV irradiated and compared the UV-induced skin cancer 
susceptibility of wild-type mice to mice lacking functional pol eta, pol iota, or both. 
Pol iota deficiency alone had no effect on cancer susceptibility in mice with 
functional pol eta. Unexpectedly, however, UV-induced skin tumors in pol iota-
deficient mice developed four weeks earlier in mice concomitantly deficient in pol 
eta. Collectively, these data reveal functions for pol iota in bypassing UV 
photoproducts. Additionally, these data indicate that pol iota acts as a tumor 
suppressor by a mechanism that is presumably distinct from is TLS functions. 
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MATERIALS AND METHODS 
GENERATION OF DOUBLE KNOCKOUT MICE 
In an earlier studl9 an ES cell line derived from pol t-deficient 129 mice 
was used to generate pol eta knockout mice. In that study99 chimeric mice were 
bred with B6 mice to produce F1 pol eta. heterozygotes that were then 
intercrossed to generate the F2 mice. The present study began by PCR-
genotyping 595 F2 mice twelve of which were pol eta +/-/ pol iota -/-. These mice 
were intercrossed to generate the double homozygous mice studied here. 
GENERATION AND GROWTH OF PRIMARY EAR FIBROBLASTS 
Primary fibroblasts derived from ear punches were grown at 3]0 under 
hypoxic conditions (2-3% O2, 5% CO2). These conditions were previously 
reported to increase the number of population doublings and lengthen the time 
before senescense of primary murine cells 100. Nitrogen gas was used to sustain 
hypoxic conditions in the incubators using an oxygen control module (Biospherix, 
Ltd., PROOX model 110). Cells were maintained in MEM-a (Cambrex Bio 
Science Walkersville, MD) supplemented with 10% FBS (Hyclone Laboratories, 
Logan, UT), 2mM glutamine, nonessential amino acids (Mediatech, Inc. Herndon, 
VA), penicillin (100 units/ml), streptomycin (100 Ilg/ml) for all assays with the 
exception of the 6-thioguanine (6-TG) screening, which utilized DMEM 
(Mediatech, Inc. Herndon, VA). 
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CYTOTOXIC AND MUTAGENIC EFFECTS OF UV IRRADIATION 
Fibroblasts were assayed for cytotoxic and mutagenic responses to 
UV254nm radiation at early passages (6-8 population doublings) after primary 
cultures were established. The UV source was a Spectroline germicidal lamp that 
emits short wave UV with a peak emission at 254nm. The energy emitted by the 
light was quantified using an International Light model IL 1700 radiometer and a 
sensor fitted with a 254nm filter and W diffuser. The height of the light was 
adjusted to deliver 0.1-0.2 J/m2/sec at the level of the cells. 
A series of independent populations (1.5 x 106 cells each, plated on 150-
mm-diameter plates) were treated with UV254nm at fluences of 0-12 J/m2 for pol 
eta +/+ cells or 0-6 J/m2 for pol iota -/- cells. Prior to UV exposure, the culture 
medium was aspirated and the cells were washed with PBS (pH 7.4). Sufficient 
dishes were used to ensure at least 1.0 x 106 surviving cells. Each dish was 
allowed 3-5 days of growth before trypsinization and passage of 1.5 x 106 cells. 
After 8-9 days of post-irradiation expression, 0.5-1.0 x 106 cells were selected for 
6-thioguanine (6-TG) resistance (TG r) as described below. Cytotoxic responses 
to radiation were established by plating the cells at cloning density and 
measuring colony forming ability. The media of cells exposed at cloning density 
were replaced with fresh medium after 24 hours and 7 days post-irradiation and 
stained at ~ 14 days. Colony forming ability was also determined at the time of 
TG r selection by plating the cells at cloning density in nonselective medium. This 
value was used to correct the observed frequency of mutants. After 14 - 20 days, 
TG r clones were isolated in RNase free PBS for Hprt coding region amplification 
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(described below). After colony isolation, plates were stained for missed colonies 
and mutant frequency was determined, defined as the number of observed TG r 
clones per 106 clonable cells (corrected for cloning efficiency). The significance of 
differences in frequencies between polymerase genotypes was calculated using 
the Fisher's exact test. 
AMPLIFICATION AND SEQUENCING OF HPRT CDNA 
Isolation of TGr clones, reverse transcriptase-PCR (RT -PCR) of the coding 
region of the Hprt gene, and sequence analysis of the PCR products was done 
as described below. After the 8 - 10 day expression period dishes were visually 
inspected in a dark room under flashlight for apparent (macroscopic) thioguanine 
resistant (TGr) colonies. Individual clones were circled before aspirating the 
media washing the dish with sterile PBS (pH 7.4). A dry sterile cotton swab was 
used to dry around the resistant colony before addition of 10 )11 of trypsine. A 
micropipette was then used to pull the colony from the dish. Pulled colonies were 
put into a sterile 50 )11 microfuge tube filled with 500 )11 sterile PBS (pH 7.4) to 
dilute trypsin. The cells were pelleted by centrifugation at 15,000 x g for 10 
minutes at 4°C and samples frozen at -80°C (for later amplification of the Hprt 
coding region). Dishes were then stained and total colonies counted to determine 
mutant frequency. Amplification of Hprt cDNA from small clones was adapted 
from Yang et a/101 . The cells were either directly processed or frozen at -80°C 
before cDNA preparation. While on ice the cells were lysed by adding 10 III of 
Reverse Transcription (RT) lysis buffer containing1 X Superscript III RT buffer 
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(Invitrogen Corp), 2 units/ill RNASE OUT (Invitrogen Corp), 25 ng/ 111 Oligo dT 
(20 mer, Integrated DNA Technologies), 10 mM OTT, 500 11M dNTPs (Invitrogen 
Corp), 10 units/ill Superscript III RT (Invitrogen Corp), 2.5% NP-40, H20 to 10111. 
The resuspended cell pellet was transferred to a 200 111 PCR tube and incubated 
for 50 minutes at 50°C. The reverse transcription (RT) reaction was terminated 
by heating to 70°C for 10 minutes. Amplification was performed through two 
rounds of PCR using inner and outer sets of primers. First round PCR reaction 
mix contained 5 111 cDNA, 1 X PCR buffer (Invitrogen Corp), 1.5 mM MgCI2 
(Invitrogen Corp), 200 11M dNTPs (Invitrogen Corp), 0.2 11M outer primer A 
(Integrated DNA Technologies GGC TTC CTC CTC AGA CCG CT), 0.2 11M outer 
primer B (Integrated DNA Technologies ACA TCA ACA GGA CTC CTC GT), 2 
units Platinum Taq polymerase (Invitrogen Corp), H20 to 50 111. Using a 
Stratagene Robocycler the reaction was held at 94°C for 3 minutes, then 30 
cycles of 94 °c for 30 seconds, 57°C for 30 seconds, 72°C for 1 minute, and 
final extention using 72°C for 10 minutes. Second round PCR mix contained 1 111 
of 1 sl round product, 1 X PCR buffer (Invitrogen Corp), 1.5 mM MgCI2 (Invitrogen 
Corp), 200 11M dNTPs (Invitrogen Corp), 0.2 11M inner primer 3 (Integrated DNA 
Technologies TTT TGC CGC GAG CCG ACC GG), 0.2 11M inner primer 4 
(Integrated DNA Technologies ATT TGC AGA TTC AAC TTG CG), 2 units 
Platinum Taq polymerase (Invitrogen Corp), H20 to 50 111. Second round PCR 
Program using Stratagene Robocycler consisted of 94°C for 3 minutes followed 
by 20 cycles of 94 °c for 30 seconds, 57°C for 30 seconds, 72°C for 1 minute 
and final extension of 72 DC for 10 minutes. The final product was a.nalyzed using 
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5 fll of 2nd round product on 1 % agarose prior to sequencing. The sequence of 
both DNA strands was determined by automated DNA sequencing. For 
sequencing dRhodamine dye terminator chemistry (Applied Biosystems) was 
used along with the same inner primer 3 (Integrated DNA Technologies TTT 
TGC CGC GAG CCG ACC GG), and primer 4 (Integrated DNA Technologies 
ATT TGC AGA TTC AAC TTG CG) used during second round PCR. 
IRRADIATION OF MICE 
Eight to twelve week old mice were used for UV irradiation. All of the mice 
were litter-mates and had their backs shaved once a week during the UV 
irradiation period. Mice were irradiated with UV-B light. The UV source was a 
bank of two UV-B lamps (Blak-Ray lamp Model XX-15M, Ultraviolet Products, 
Inc., Upland, CA 91786, USA) that emit wavelengths in the 280-370 nm range, 
with a peak at 302 nm. UV-B flux was measured by a UVX digital radiometer 
(Model UVX-31, Ultraviolet Products, Inc., Upland, CA). UV irradiation was 
terminated upon initial observation of tumor formation. 
HISTOLOGICAL ANALYSIS OF MOUSE TISSUE AND SKIN TUMORS 
Mice were sacrificed via CO2 inhalation for whole body tumor and tissue analysis. 
Tissue and tumors were isolated and fixed in Bouin's solution. The tissue was later 
stained with haematoxylin and eosin (H&E) stain and examined. 
31 
RESULTS 
GENERATION OF MICE AND PRIMARY FIBROBLASTS 
Mice with homozygous deficiencies in pol iota and pol eta were generated 
by mating F2 pol eta +/-/ pol iota -/- mice. The progeny included :~3 pol eta +1+/ 
pol iota -/- mice, 48 pol eta. +/-/ pol iota -/- mice, and 30 pol eta. -/-/ pol iota -/-
mice. The multiple progeny indicates that mice deficient in both pol eta and pol 
iota develop normally and are viable. These mice were used to examine whether 
pol iota has a role in response to irradiation with UV light. At the same time mice 
were being irradiated to examine the susceptibility of the mice to UV light-
induced skin cancer (see below), primary fibroblasts were isolated from ear 
biopsies. Primary fibroblasts were successfully derived from wild-type mice and 
mice deficient in pol eta only, pol iota only and both pol eta and pol iota (Table 1). 
Different cell line numbers/letters indicate the fibroblast originated from separate 
mice. 
Primary cells grew well in normal cell culture media (as described in the 
Materials and Methods section). Growing the primary fibroblast in hypoxic 
conditions lengthened the time before senescence with senescence typically 
occurring around 20 population doublings and/or five cryogenic freezes. 




Background Cell Line 
129 (83) Pol iota +/+ Pol eta +/+ 
129 (35d) Pol iota +/+ Pol eta +/+ 
129 (47) Pol iota +/+ Pol eta +/+ 
129 (70) Pol iota -/- Pol eta +/+ 
129 (69) Pol iota -/- Pol eta +/+ 
129 (75d) Pol iota +/+ Pol eta -/-
129 (34d) Pol iota +/+ Pol eta -/-
129 (48) Pol iota +/+ Pol eta -/-
129 (71) Pol iota -/- Pol eta -/-
129 (73) Pol iota -/- Pol eta -/-
Table 1. Fibroblast Cell Lines. Cell lines that were successfully derived from 
wild-type mice and mice deficient in pol eta only, pol iota only, and both pol eta 
and pol iota. Different cell line numbers/ letters indicate the fibroblast originated 
from separate mice. 
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SURVIVAL OF PRIMARY MOUSE FIBROBLASTS FOLLOWING UV 
IRRADIATION 
The influence of mouse genotype on survival of primary dermal fibroblasts 
after irradiation with UV254nm was measured by colony forming ability (Figure 4). 
Cells deficient in pol eta alone were moderately sensitive to killing by UV 
irradiation at a dose 2.8 J/ m2 resulting in 37% survival (037) (Figure 4). In either 
the pol eta deficient or pol eta proficient background, cells deficient in pol iota 
were more sensitive to UV-induced cytotoxicity (Figure 4, filled squares and 
diamonds). Statistical significance of the reduced survival of pol iota deficient 
cells was determined by polynomial regression analysis, with the best fit provided 
by cubic polynomials. This analysis revealed that the percent survival for pol eta 
+/+ pol iota -/- cells was significantly lower than for pol eta +/+ pol iota +/+ cells (p 
= 0.018). This analysis also showed that the percent survival for pol eta -/- pol 
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Figure 4. Survival of primary mouse fibroblasts following UV irradiation. 
The influence of mouse genotype on survival of primary dermal fibroblasts after 
irradiation with UV254nm was measured by colony forming ability, as described in 
Methods. The fluence required to reduce the survival of pole eta (pol '1) +/+ pol 
iota (poll) +/+ cells to 37% of the unirradiated control (D37) was 8 J/m2 . This was 
reduced to -2.8 J/m2 in the cells derived from pol eta (pol '1) -/- pol iota (poll) +/+. 
Statistical significance of the reduced survival of pol iota deficient cells was 
determined by polynomial regression analysis, with the best fit provided by cubic 
polynomials. This analysis revealed that the percent survival for pol eta +/+ pol 
iota -/- cells was significantly lower than for pol eta +/+ pol iota +/+ cells (p = 
0.018). This analysis also showed that the percent survival for pol eta -/- pol iota -
/- cells was significantly lower than for pol eta -/- pol iota +/+ cells (p = 0.001). 
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UV LIGHT-INDUCED MUTAGENESIS AT THE HPRT LOCUS IN PRIMARY MOUSE 
FIBROBLASTS 
The hypoxanthine-guanine phospho ribosyl transferase (Hprt) gene is a useful 
target for studying somatic mutations. This target gene is located on the X-chromosome 
and encodes the Hprt protein 102. Hprt exists in low levels in all somatic tissue 
constituting .005-.01 % of total mRNA 103. This protein's activity is required for the 
phosphoribosylation of hypoxanthine and guanine and its enzymatic activity is part of 
the salvage pathway for purine nucleic acid biosynthesis. This enzyme is also 
responsible for the phosphoribosylation of purine analogs such as 8-azaguanine and 6-
thioguanine (6-TG) which enables them to be incorporated into DNA 104. Thus, when one 
of these purine analogs is present in cell culture medium, the cells incorporate these 
analogs into their DNA. This incorporation severely taxes DNA mismatch repair systems 
causing cell death. If however, mutations are present in the Hprt gene, which abolish 
functional enzyme, the cells do not incorporate the analog into the DNA and survive. 
This purine salvage pathway provides an efficient mechanism to study induced 
mutations in the Hprt gene through the selection of purine analog mutants 105. While any 
of the purine analogs may be used to select for Hprt mutations, issues such as 
concentration, lack of efficacy, and selection time has lead 6-TG to become the 
standard in Hprt mutant selection 106. The studies covered in this dissertation utilize 6-
thioguanine as the purine analog for selection, the mutants of which are indicated as 
thioguanine resistant (TGr). 
Table 2 reports individual experiments after irradiation of cells plated on 
three 150 mm-diameter dishes at a density of 104 cells/ dish. These results 
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indicate the percent survival, number of mutants observed, percent survival, 
number of cells selected for and mutant frequencies for three different doses. 
Mutation frequency results are summarized and compared in Figure 5. 
Compared to wild-type fibroblasts (Figure. 5, open diamonds), a deficiency 
in mouse pol eta alone resulted in increased UV irradiation-induced mutagenesis 
at the endogenous Hprt locus (Figure. 5, open squares). Interestingly, in pol eta-
deficient cells in which pol iota was also deficient, the mutant frequency was also 
reduced (Figure. 5, closed squares), implicating pol iota in mutagenic TLS when 
pol eta is absent. Even when pol eta is proficient, pol iota deficiency reduced UV 
induced mutagenesis (Figure 5, compare open to closed diamonds), again 
implicating mouse pol iota in bypass of UV photoproducts. The fact that the UV-
induced mutant frequency in cells that are deficient in both pol eta and pol iota 
(Figure 5, filled boxes) is higher than the spontaneous mutant frequency (-1 O·s) 
indicates that a third polymerase performs mutagenic bypass of photoproducts. 
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TGr Cells Mutants Mutants Per 10
0 
Cell UV Percent Per 106 Clonable Cells 
Line (J/m2) Survival Clones Selected Clonable minus Observed x 106 Cells Background 
47 0 100 2 .5 12 107:t18 
7 50 88 4.5 119 
Iota +1+ 
83 0 100 60 .5 255 245 Eta +1+ 8 27 230 1 500 
35d 0 100 4 .5 17 198 
9 10 86 1 215 
70 0 100 0 .5 0 42:t12 
7 32 53 3.5 42 
Iota -1-
69 0 100 0 .5 0 31 Eta +1+ 8 17 13 1 31 
69 0 100 3 .5 26 67:t13 
9 10 41 2 93 
75d 0 100 0 .5 0 86 
2.5 71 33 1 86 
Iota +1+ 
34d 0 100 6 .5 33 69 Eta -1- 3 40 43 1 102 
48 a 100 0 .5 0 830:t78 
3.8 25 805 2.5 830 
73 0 100 0 .5 0 78:t22 
2.5 46 59 2 78 
Iota -1-
73 0 100 a .5 0 239 Eta -1- 3 15 32 1 239 
71 0 100 0 .5 0 245:t17 
4 13 107 1.5 245 
Table 2. Mutant frequencies of individual cell lines after exposure to 254nm 
UV light. Cells were plated on three 150 mm-diameter dishes at a density of 104 
cells/dish to determine mutant frequency at three varying dose, column 3. Cells 
were also plated at cloning density to determine survival, column 4. Column 5 list 
total mutant clones observed. Total mutant corrected for cloning efficiency (not 
listed) yields the number mutants per 106 clonable cells is listed in column 5. 
Column 6 list mutants per 106 cion able cells after subtracting background. 
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Figure 5. Frequency of thioguanine-resistant (TGr) clones as a function 
of survival after UV-irradiation. Cells were plated on three 150 mm-diameter 
dishes at a density of 104 cells/cm2 to determine mutant frequency, or at cloning 
density to determine survival. After attachment, plates were irradiated with UV 
fluences determined from the data in Figure 4 that were estimated to give an 
expected survival of 20- 40%. The actual survival in the mutagenesis 
experiments were determined as in Figure 4 and are plotted on the X-axis. The 
corresponding mutant frequency at each survival is plotted on the Y-axis. Each 
point represents the mean of three independent dishes at the indicated survival, 
plus or minus 1 standard deviation. Mutant frequency is defined as the number 
of TGr clones per million clonable cells. Each data point represents at least two 
independent experiments in which 2-4 x 106 surviving cells were selected after 
UV irradiation and an 8-9 day expression period. The data have been corrected 
for cloning efficiency on the day of selection and the spontaneous background 
mutant frequency (10'5) has been subtracted. The arrows indicate the reduction 
in mutant frequency when pol I is disrupted in the pol eta-deficient background 
(larger arrow) and in the pol eta-proficient background (smaller arrow). 
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SPECIFICITY OF UV-INDUCED MUTAGENESIS 
To discover the types and locations of pol iota-dependent UV-induced 
mutations, we sequenced independent UV-induced Hprt mutants derived from 
cells of each of the four genotypes. The results are summarized in Table 3 and 
presented in detail as Tables 4, 5, 6, and 7 at the end of the chapter. In all four 
instances, we analyzed mutant clones for exposures that resulted in -37% 
survival for that genotype (Figure 5). 
To further understand the strand specificity of UV-induced mutagenesis 
we determined the strand containing the dipryimidine sequence in the case of 
each targeted base substitution. The proportion of mutations that arose from 
putative photoproducts in either strand was multiplied by the mutant frequency 
induced at the D37 for each of the four genotypes. This data is summarized as 
presented in Figure 6. 
WILD-TYPE CELLS 
Among 36 Hprt mutant clones from wild-type cells, 31 base pair 
substitutions were found (Table 3 and Table 4 at the end of the chapter). 
Twenty-seven substitutions occurred at dipyrimidines, indicating that dipyrimidine 
photoproducts are responsible for the majority of the UV-induced mutations. 
Interestingly, 22 of the 27 substitutions are inferred to result from bypass of a 
dipyrimidine photoproduct on the non-transcribed strand (Table 4). This 
represents a 4.5 fold bias in favor of mutations templated at dipyrimidines on the 
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non-transcribed strand compared to the transcribed strand (Figure 6, 49 x 10-6 
versus 11 x 10-6 , P <0.0001). 
POL ETA-DEFICIENT CELLS 
A deficiency in mouse pol eta alone resulted in an -7-fold increase in 
induced mutant frequency (Table 3, compare 80 x 10-6 to 550 x 10-6). Sequence 
analysis of UV-induced Hprt mutants in pol eta-deficient fibroblasts (Table 3 and 
Table 5 at the end of the chapter) revealed increased frequencies for several 
types of single base substitutions (up to 40-fold for T-A to C-G substitutions), for 
tandem double base substitutions (>1 O-fold) and for exon deletions (20 fold). 
The exon deletions could result from splicing abnormalities caused by mutations 
in splice donor or acceptor sites. Most substitutions were at dipyrimidines (Table 
5). However, the bias in favor of mutations templated at dipyrimidines in the 
nontranscribed strand was reduced from 4.5-fold in wild-type cells to 2.9 fold in 
-6 -6 
pol eta-deficient cells (Figure 6, 290 x 10 versus 100 x 10 ). This is consistent 
with an earlier study using XP variant cells99 . This study also shows that pol eta 
is acting to preferentially bypass photoproducts in the transcribed strand. Of 
notable importance is the high proportion of CG to AT tranversions, 78% (7/9) of 
which arose from dipyrimidines on the transcribed strand. 
In the present study of asynchronously growing mouse cells lacking pol eta, 
similar frequencies and proportions of transitions and transversions were 
observed following UV irradiation, and the frequency of C to T transitions was 
100 x 10-6 (Table 3). The data reported here in mouse cells has some 
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discrepancies with that presented in human XP varient lines52 . In particular, in 
that study when XP variant cells deficient in pol eta52 were irradiated at the 
beginning of S-phase the UV-induced substitutions included 13 transitions and 
17 transversions. The calculated frequency of C to T transitions was 130 x 10-6 . 
However, when the XP variant cells were irradiated in the G1 phase to allow time 
for repair before replication, transversions exceeded transitions by 11 :4, and the 
calculated frequency of UV-induced C to T transitions was only 18 x 10-6 . The 
differences between our study in mouse cells and human XP variant cells 
irradiated in the G1 could partially be related to the relationship between repair 
and replication. It could also or additionally be a result of the amount of time 
available for deamination of cytosine-containing photoproducts to occur. The 
later is particular noteworthy since rodent cells have a reduced level of global 
nucleotide excision repair compared to human cells. 
POL IOTA-DEFICIENT CELLS 
Fibroblasts deficient in pol iota have UV -induced total mutant frequencies 
and base substitution frequencies that are more than 2-fold lower than for wild-
type cells. This decrease observed in pol iota deficient cells almost brings the 
mutation frequency to background levels. Specifically, wild-type cells after UV 
irradiation at D37 have a mutational frequency of 80 mutants per 10-6 clonable 
cells. Pol iota removal lowered this frequency to 32 mutants per 10-6 clonable 
cells (see Table 3, compare columns 1 and 3). These differences are extremely 
significant resulting in a p value of <0.0001. 
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Among 18 base substitutions (Table 6, at the end of the chapter), 14 were at 
dipyrimidines as listed in column three (Table 3). Notably, the dipyrimidine was 
on the non-transcribed strand for 10 of these, such that the non-transcribed to 
transcribed strand bias was 2.4-fold (Figure 6., 17 x 10-6 versus 7 x 10-6 , P = 
0.064). This is less than the 4.5-fold bias observed in wild-type cells. This 
decrease in strand bias after UV irradiation suggests that some of the strand bias 
observed in wild-type cells is a result of pol iota. Specifically pol iota is working 
preferentially on the non-transcribed (leading) strand in an error prone fashion. 
CELLS DEFICIENT IN BOTH POL ETA AND POL IOTA 
Fibroblasts deficient in pol eta and pol iota had UV-induced mutant 
frequencies (Table 3, column 4), that in comparison to cells deficient in pol eta 
alone (Table 3, column 2), were reduced for all mutations. Additional reduction 
was also observed for total substitutions, transitions, transversions, tandem 
double base substitutions and exon deletions. These 4- to 5-fold differences are 
significant with a p value of :50.05. Among 15 substitutions at dipyrimidines, 
seven are inferred to result from bypass of a lesion on the non-transcribed strand 
and eight are inferred to result from bypass of a lesion on the transcribed strand 
(Table 7). The fact that deficiency in both pol eta and pol iota eliminated the 
strand bias 41 x 10-6 on the non-transcribed strand versus 46 x 10-6 on the 
transcribed strand (Figure 6), suggests that this bias depends on both 
polymerases. Also noteworthy is that the UV-induced mutant frequency of 
fibroblasts deficient in both pol eta and pol iota is 120 x 10-6 (Table 3, column 4), 
this is much higher than the spontaneous mutant frequency in un-irradiated cells 
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(1 x 10-5). This is direct evidence that even in cells lack po eta and pol iota there 
is an elevated mutation frequency after UV irradiation and this indicates that at 
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~2 (0) 6 (1) 
2 (1) 29 (5) 
~2 (0) ~6 (0) 
24 (14) 
Tandems ~2 (0) 23 (2) 5 (3) 6 (1) 
Transitions 31 (14) 180 (16) 8 (5) 41 (7) 
e-G ~ T-A 29 (13) 100 (9) 8 (5) 23 (4 I) 
T-A ~ e-G 2 (1) 80 (7) ~2 (0) 17 (3 1) 
Transversions 29 (13) 180 (16) 10 (6) 41 (7) 
e-G~A-T 4 (2) 100 (9) 2 (1) 23 (4 1) 
e-G ~ G-e ~2 (0) 11 (1) ~2 (0) ~6 (0) 
T-A ~ A-T 13 (6) 57 (5) 8 (5) 17 (31) 
T-A ~ G-e 11 (5) 11 (1) ~2 (0) ~6 (0) 
Table 3. UV-induced Hprt mutation frequencies in mouse primary 
fibroblasts aFrequency measurements were determined for at least 6 
independent assays and using primary fibroblasts isolated from at least 2 
independent mice. bMutation frequencies were determined at UV exposures 
resulting in 37% cell survival. cNumbers in brackets are the number of 
independent mutants sequenced (Tables 4-7). dNumbers in parentheses are the 
number of independent mutations observed (Tables 4-7). 8Large deletions are 
primarily deletions of exons (Tables 4-7). IThree mutants contained multiple 
mutations separated by more than 100 nucleotides (see Supplemental Tables 7). 
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Figure 6. Strand specificity of UV-induced mutagenesis. The strand 
containing the dipryimidine sequence was determined in the case of each 
targeted base substitution. The proportion of mutations that arose from putative 
photoproducts in either strand was multiplied by the mutant frequency induced at 
the 0 37 for each of the four genotypes as presented in Figure 5. Non-transcribed 
to transcribed strand bias was lower for pol t deficient cells compared to wildtype 
2.4-fold This is less than the 4.5-fold bias observed in wild-type cells. Non-
transcribed strand was additional reduced from 4.5-fold in wild-type cells to 2.9-
fold in pol 'l-deficient cells. Double knockout eliminated strand bias suggesting 
that strand bias depends on both polymerases. 
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SUSCEPTIBILITY OF POL ETA AND POL IOTA DOUBLE KNOCKOUT MICE 
TO UV-INDUCED SKIN CARCINOMA 
To determine the susceptibility of pol eta -f- I pol iota -f- mutant mice to UV 
light-induced skin carcinoma, sets of littermates were shaved on part of their 
backs once a week, UV irradiated three times a week at 3.75 kJ/m 2 . These mice 
were examined for skin tumors each week. Irradiation was for 20 weeks and was 
discontinued when the first skin tumor was observed. Twelve pol eta -1- I pol iota 
-1- mutant mice, 13 pol eta +1- I pol iota -1- mutant mice and nine pol eta +1+ I pol 
iota -1- mutant mice were treated and examined. These results were then 
compared to those reported earlier for wild-type and pol iota -1- mutant mice99. 
Similar to results with wild-type mice, (Figure 7, open squares) none of the 13 pol 
eta +1- I pol iota -1- mutant mice or the nine pol eta +1+ I Pol iota -1- mutant mice 
developed skin tumors over the 20 week course of irradiation (data not shown). 
Similar to results with the pol eta -f- mutant mice 99 the irradiated ears of the pol 
eta -1- I pol iota -1- mutant mice became darker, curved and atrophied, while 
littermate controls (e.g., pol eta +1+ I pol iota -1- mice) did not show such 
abnormalities or develop skin tumors even after 30 weeks of exposure. More 
importantly, UV-induced skin tumors developed in the double knockout pol eta -I-
I pol iota -1- mice starting at week 8 of irradiation. All 12 mice developed skin 
tumors by week 13 (Figure 7, open circles). This data shows that time for tumor 
formation in pol eta -1- I pol iota -1- is earlier than for pol eta knockout mice. 
Specifically, the first UV induced skin tumors in pol eta null mice at week 12 
(compared to 8 in pol eta -1- I pol iota -1-) of irradiation and the last at week 18 
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(compared to 13 of pol eta -/- / pol iota -/-) (Figure 7, open diamonds), 
reproduced from 99 . This pol iota dependent difference in time to skin tumor 
formation is statistically significant, with low p values as determined by three 
different statistical tests, a log rank test (p value = <0.0001), at-test (p value = 
<0.0001) and a Mann-Whitney test (p value = <0.0002). Histological analysis of 
skin tumors (data not shown) revealed phenotypes in double knockout mice that 
were indistinguishable from those of the pol eta null knockouts. Both developed 
tumors that formed from squamous cell carcinoma in situ and advanced to 
invasive carcinomas. Thus, loss of pol iota increases the susceptibility of pol eta 
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Figure 7. UV light-induced skin cancer in mice. Mice were shaved once per 
week and irradiated three times per week with 3.5 kJ/m2, for twenty weeks or 
until the first skin tumor arose. Mice were inspected weekly for the development 
of skin tumors. Results with 12 pol eta (pol 11) -/- / pol iota (pol I) -1- mice (open 
circles) are compared with results previously reported99 for 14 wild-type mice 
(open squares) and 12 homozygous pol eta knockout mice (open diamonds), 
eight of which were fol iota +1+ and four of which were pol iota +1-. We also 
irradiated 13 pol eta + - / pol iota -1- mice and nine pol eta +1+ / pol iota -1- mice, none 
of which developed skin tumors after 20 weeks of irradiation (not plotted). In fact, 
the latter mice did not develop skin tumors after more than 41 weeks. 
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DISCUSSION 
This study provides new insights into the biological function of pol iota and 
has several implications regarding TLS and the mutagenic and carcinogenic 
effects of UV radiation. 
POL IOTA PARTICIPATES IN TRANSLESION DNA SYNTHESIS 
As expected based on results with human cells52,107,108 and mouse 
embryonic fibroblasts99 , primary fibroblasts deficient in mouse pol eta alone are 
moderately sensitive to killing by UV irradiation compared to wild-type cells 
(Figure 4). Also, as expected based on results with XPV cells lacking functional 
pol eta52 , a deficiency in mouse pol iota strongly enhances UV light-induced 
mutagenesis at the endogenous Hprt locus (Figure 5). This is the starting point 
for the novel observation that UV mutagenesis in pol eta deficient cells is 
suppressed by inactivation of pol iota (Figure 5, Table 3). This suggests that pol 
iota participates in mutagenic bypass of UV photoproducts when pol eta is 
deficient. The fact that pol iota deficiency also suppresses UV-induced 
mutagenesis in pol eta proficient cells (Figure 5, Table 3) suggests that TLS is a 
normal function of pol iota, not only a replacement function when another TLS 
enzyme is missing. 
The interpretation that pol iota can conduct mutagenic photoproduct bypass 
in mouse cells is consistent with earlier biochemical studies suggesting that pol 
iota contributes to enhanced UV mutagenesis in pol eta deficient XPV cells68 . 
50 
Our results however differ from a recent study in which pol iota expression in 
cultured 293T cells was decreased using siRNA57. In that study, decreased pol 
iota expression had no effect on UV-induced mutagenesis. In that study 
mutagenesis was detected using the supF gene present on an 
extrachromosomal shuttle vector and lead to the conclusion that that pol iota has 
no significant role in UV lesion bypass and mutagenesis. Experimental 
differences between that study and the ones presented here could account for 
the different conclusions. These differences include the reporter (a gene in a 
shuttle vector versus an endogenous chromosomal gene) used to monitor 
mutagenesis and possible incomplete silencing of pol iota in 293T cells. 
The extent to which pol iota contributes to bypass of UV light induced 
lesions may partly depend on the type of photoproduct. Although pol eta 
bypasses cis-syn thymine-thymine dimers, it cannot bypass or insert nucleotides 
opposite the two distorted bases of a 6-4 photoproduct. In contrast, pol iota 
inserts nucleotides opposite 6-4 photoproducts. Because pol iota does not 
extend the resulting primer termini, other polymerases, e.g., pol kappa (pol K) or 
pol zeta (pol s), have been suggested to perform that task. Thus pol iota's role 
may sometimes be subservient to pol eta, perhaps explaining why pol iota's 
affect on UV mutagenesis is about 2-fold lower when pol eta is present (Table 3). 
Perhaps pol iota predominantly inserts nucleotides opposite photoproducts not 
efficiently bypassed by pol eta. While that could occur at the replication fork, it 
may also possibly occur during filling of gaps left in the DNA after the fork has 
moved on 109. However, when pol eta is missing, pol iota may assume a 
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somewhat larger role in bypassing UV photoproducts, consistent with a 5-fold 
mutagenic decrease when pol eta is absent (Table 3). Moreover, the details of 
TLS by pol iota could differ in the presence or absence of pol eta because the 
two enzymes physically interact and because pol iota localization to foci in UV 
irradiated human cells is reduced in pol eta-deficient cells 110 These ideas, and 
the identity of the photoproducts responsible for mutagenesis, could be tested by 
combining the pol eta and pol iota defects studied here with mice defective in 
global and transcription-coupled nucleotide excision repair, or with mice that 
express photolyases that selectively remove cyclobutane pyrimidine dimers or 6-
4 photoproducts 111. 
The specificity of strand bias in Table 3 implies that pol iota contributes to 
multiple types of UV-induced base substitutions. The pol iota-dependent 
substitution specificity in Table 3 is generally consistent with the insertion 
specificity of pol iota. Pol iota has been shown to preferentially misinserts dNTPs 
opposite template pyrimidines66 . The exception may be the high rate of C to T 
transitions that could result from incorporation of dAMP opposite a damaged 
pyrimidine (Table 3). UV-induced C to T transitions may primarily result from 
"correct" insertion of dAMP opposite uracil that results from deamination of 
cystosine in photoproducts 112. Based on that idea, the ability of pol iota to 
preferentially insert dGMP opposite U could theoretically be antimutagenic for 
cytosine deamination in general70 and/ or during TLS of photoproducts 113 That 
hypothesis is not supported by our observations. The data presented here rather 
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support that pol iota promotes rather than suppresses UV-dependent 
mutagenesis for C to T transitions (Table 3). 
POL ETA AND POL IOTA PARTICIPATE IN STRAND-SPECIFIC DNA 
TRANSACTIONS 
In wild-type cells or cells deficient in pol eta alone or pol iota alone, there 
is a bias for UV-induced base substitutions at dipyrimidines on the non-
transcribed DNA strand (Figure 6). This bias may reflect removal of 
photoproducts from the transcribed strand by transcription-coupled nucleotide 
excision repair, since such repair is known to alter the mutation spectrum 107,114. 
Relative to wild-type cells, the strand bias is slightly reduced when pol eta or pol 
iota is deficient, and is eliminated when both enzymes are deficient (Figure 6). 
This suggests that both polymerases contribute to modulating mutagenic bypass 
of UV photoproducts in a strand-specific manner. The strand biases could be 
related to differences in leading versus lagging strand replication enzymology 
(see below), transcription, or perhaps a more prominent role in bypassing a 
subset of photoproducts that remain in the non-transcribed strand for a longer 
time. 
STRAND BIAS FOR UV-INDUCED C-G TO A-T TRANSVERSIONS 
The exception to the non-transcribed strand bias is that the majority of C-
G to A-T substitutions are inferred to result from lesions in the transcribed strand. 
This observation in mouse cells is similar to results in XP variant cells52 . In 
human cells, a chromosomal origin of replication is located 3' to exon 1 of Hpd 15 
implying that the transcribed strand of Hprt is replicated as the leading strand 
53 
template. That interpretation is consistent with studies of replication in extracts of 
XP variant cells, which generates a high proportion of C-G to A-T substitutions 
arising from replication of photoproducts on the leading strand template51 . By 
extrapolation, the C-G to A-T substitutions in the present study may result from 
leading strand replication, leading to the further speculation that the non-
transcribed strand bias discussed above could reflect TLS during replication of 
the lagging strand template. In addition to CPDs and 6-4 photoproducts, UV 
irradiation also generates oxidative damage to DNA. Thus, oxidative lesions like 
8-oxo-guanine may contribute to the G-C to T -A transversions observed in 
irradiated fibroblasts, and possibly to the skin cancer. However, this may be 
unlikely since monobasic forms of DNA damage induced by the wavelengths 
used in the present study occur at less than 1 % of the frequency of dipyrimidine 
photoproducts116. Interestingly, the CG to AT transversions on the transcribed 
strand largely originate when pol eta is deficient, suggesting that they are made 
by a different TLS polymerase, such as pol iota (Table 6, in pol eta deficient 
cells) or perhaps pol zeta or pol kappa (Table 7, double deficient-cells). 
PARTICIPATION OF AT LEAST ONE OTHER POLYMERASE IN BYPASS OF 
UV PHOTOPRODUCTS 
The observation that the UV-induced mutant frequency in cells deficient in 
both pol eta and pol iota (Table 3), is much higher than the spontaneous mutant 
frequency of un-irradiated cells indicates that at least one other polymerase 
performs mutagenic TLS. One candidate is pol zeta. Notably, yeast pol zeta has 
54 
recently been shown to efficiently bypass UV photoproducts when assisted by 
accessory proteins 117. This polymerase, despite belonging to the 8-family, which 
mostly contains high fidelity replicative polymerases remarkably copies 
undamaged templates with low fidelity l18. 
POL IOTA HAS A FUNCTION IN DELAYING THE ONSET OF UV LlGHT-
INDUCED SKIN CANCER 
There are well known correlations between increased mutagenesis and 
increased carcinogenesis, and there is considerable evidence to support the 
hypothesis that a mutator phenotype promotes multistage carcinogenesis 119. 
Thus, it was unexpected to observe that UV light-induced skin cancer is 
suppressed by pol iota (Figure 7), even though pol iota appears to contribute to 
mutagenic bypass of photoproducts (Figure 5 and Table 3). Several hypotheses 
can be considered. It could simply be that mutagenesis at the Hprt locus in 
primary fibroblasts does not reflect rate-limiting mutations in the cell types and/ or 
genes most relevant to development of skin tumors in mice. Against this are 
similar measurements of mutagenesis at the Hprt locus in pol eta-deficient XPV 
fibroblasts that do demonstrate elevated UV-induced mutant frequencies that 
correlate with elevated susceptibility to skin cancer. It could be that the function 
of pol iota that suppresses skin cancer is simply to bypass lesions, regardless of 
whether this is performed in an accurate or mutagenic fashion. Alternatively, pol 
iota could modulate cancer susceptibility via a function other than TLS. Recent 
studies have reported that polymerases implicated in TLS also participate in 
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recombination 120,121, in nucleotide excision repair122 , and in checkpoint response 
to UV irradiation 123. If pol iota were to have similar roles in the absence of pol 
eta, then loss of function could increase susceptibility to skin cancer. In fact, loss 
of either TLS or checkpoint control due to pol iota deficiency might logically be 
anticipated to result in increased UV-induced cytotoxicity, Because the cytotoxic 
effect is not drastically increased could indicate that some photoproducts are 
initially tolerated and later bypassed by a different polymerase to yield delayed 
mutagenesis 124,125. Another possibility is that pol iota may play an important role 
in development of normal immunity, such that a pol iota deficiency would 
compromise immune suppression of skin cancer and lead to increased 
susceptibility. Against this possibility are reports that class switch recombination 
and somatic hypermutation of immunoglobulin genes appear to be normal in 129-
derived strains of mice73,126. Finally, it is formally possible that some cells in the 
double knockout mice may retain pol iota activity. As mentioned in the 
introduction, 129 mice are homozygous for a spontaneous C to A mutation in 
exon 2 that creates a nonsense codon in the Pol iota gene at Ser27, such that 
the protein should be truncated73 . Indeed, no pol iota protein was detected by 
Western blotting of testis extracts of 129 mice using an antibody raised against 
the COOH terminus of murine pol iota that recognizes full-length or mis-spliced 
variants of pol iota73 . However, a recent studi 27 has reported that crude extracts 
of brain cells from 129/J mice (but not extracts of other 129/J cells) have the 
ability to insert dGMP opposite template T in an oligonucleotide primer-template. 
The authors claim that this misinsertion activity is due to pol iota, rather than any 
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of the other DNA polymerases that can insert dGMP opposite T, and they further 
speculate that brain cells of 129 mice contain alternatively-spliced pol iota that 
retains catalytic activity. 
The observation that pol iota delays onset of skin cancer in pol eta deficient 
mice (Figure 7) is consistent with other studies suggesting a role for mouse pol 
iota in tumor suppression. The mouse Pol iota gene is on chromosome 18 and 
within the Par2 (pulmonary adenoma resistance 2) locus that is a major 
determinant of susceptibility to urethane-induced pulmonary adenomas. 
Interestingly, two strains of mice with differing lung tumor susceptibility differ in 
Pol iota gene status by 25 nucleotides and 10 amino acids, and the two enzymes 
have altered substrate specificity, suggesting that pol iota is a modifier of lung 
tumorigenesis 128. More recently, the defective Pol iota allele in the 129X1/Sv 
mouse strain that harbors the nonsense mutation in the coding sequence has 
been associated with susceptibility to urethane-induced lung tumors 129. 
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Table 4. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta +1+ Pol 
iota +I+mice. 
Strand with 
Mutant Mutation Position 
Surrounding Amino acid affected 





WT7 C-G ---> T-A 74 ATA C.QT AAT Pro ---> Leu Nontranscribed 
WT15 C-G ---> T-A 74 ATA C.QT AAT Pro ---> Leu Nontranscribed 
WT3 C-G ---> T-A 74 ATA C.QT AAT Pro ---> Leu Nontranscribed 
WT19 C-G ---> T-A 113 ATT C.QT CAT Pro ---> Leu Nontranscribed 
WT1 C-G ---> T-A 145 AGA.QTT GCT Leu ---> Phe Nontranscribed 
WT18 C-G ---> T-A 145 AGAgTT GCT Leu ---> Phe Nontranscribed 
WT512 C-G ---> T-A 145 AGAgTTGCT Leu ---> Phe Nontranscribed 
WT412 C-G ---> T-A 151 GCT gGA GAT Arg ---> STOP Nontranscribed 
WT4 C-G ---> T-A 209 AAG GQ.G GGC Gly---> Glu Transcribed 
WT14 C-G ---> T-A 508 TCT gGA AGT Arg ---> STOP Nontranscribed 
WT22 C-G ---> T-A 550 ATT gCA GAC Pro ---> Ser Nontranscribed 
WT112 C-G ---> T-A 550 ATT gCA GAC Pro ---> Ser Nontranscribed 
WT15 C-G ---> T-A 601 AGGQ.ATTTG Asp ---> Asn Transcribed 
WT40 C-G ---> A-T 134 GAC AQ.G ACT Arg ---> Met Transcribed 
WT35 C-G ---> A-T 379 ACT Q.GAAAG Gly ---> STOP Transcribed 
Mutations involving 
thymidine 
WT44 T-A ---> C-G 194 GCC CIC TGT Leu ---> Pro Nontranscribed 
WT6 T-A ---> A-T 125 CTG AIT ATG lie ---> Asn Nontranscribed 
WT51 T-A ---> A-T 125 CTG AIT ATG lie ---> Asn Nontranscribed 
WT7 T-A ---> A-T 125 CTG AIT ATG lie ---> Asn Nontranscribed 
WT28 T-A ---> A-T 245 TAC AIT AAA lie --->Asn Nontranscribed 
WT8 T-A ---> A-T 245 TAC AIT AAA lie --->Asn Nontranscribed 
WT532 T-A ---> A-T 410 ATA AIT GAC lie --->Asn Nontranscribed 
WT213 T-A ---> G-C 194 GCC CIC TGT Leu ---> Arg Nontranscribed 
WT512 T-A ---> G-C 194 GCC CIC TGT Leu ---> Arg Nontranscribed 
WT10 T-A ---> G-C 424 AAAACA ATG Thr ---> Pro Transcribed 
WT71 T-A ---> G-C 449 CTG GIT AAG Val--->Gly Nontranscribed 
WT510 T-A ---> G-e 449 eTG GIT AAG Val--->Gly Nontranscribed 
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Strand with 
Mutant Mutation Position 
Surrounding Amino acid affected 
sequencea changed dipyrimidine 
Nontandem double base 
substitutions 
WT2 CoG -7 ToA 113 } Pro -7 Leu 
CoG -7 AoT 115 A TT CgT gAT His -7 Asn 
WT12 e-G -7 T-A 113 } Pro ---1 Leu 
CoG -7 AoT 118 CgT CAT §.GA Gly -7 STOP 
Nondipyrimidine base 
substitutions 
WT31 b CoG -7 AoT 157 GAT §.TC ATG Val -7 Phe 
WT43 ToA -7 AoT GTC ATG CCG START -7 Leu 
Frameshifts 
WT83 +T 372 - 374 ACITTA ACT 
WT11 +T 655 AAAGCCIAA STOP -7 Leu 
Exon deletions 
WT96 Exon 2-3 
WT171 Exon 7 
Large insertion 
WT243 +67 bases 403,404 
aSequences of the non-transcribed (coding) strand 
bCcomplex photoproducts have been suggested to occur at ACA sequences. 
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Table 5. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta -/- Pol 
iota +1+ mice. 
Strand with 
Mutant Mutation Position 
Surrounding Amino acid affected 





H6 CoG --i ToA 74 ATA CQT AAT Pro --i Leu Nontranscribed 
H3 CoG --i ToA 74 ATA CQT AAT Pro --i Leu Nontranscribed 
H31 CoG --i ToA 464 AGC CQC AAA Pro --i Leu Nontranscribed 
H5 CoG --i ToA 464 AGC CQC AAA Pro --i Leu Nontranscribed 
H29 CoG --i ToA 464 AGC CQC AAA Pro --i Leu Nontranscribed 
H12 CoG --i ToA 544 TTT §AAATT Glu --i Lys Transcribed 
H2 CoG --i ToA 551 ATT CQA GAC Pro --i Leu Nontranscribed 
H15 CoG --i ToA 551 ATT CQA GAC Pro --i Leu Nontranscribed 
H9 C'G --i T'A 551 ATT CQA GAC Pro --i Leu Nontranscribed 
H62 CoG --i AoT 329 CAG TQA ACG Ser --i STOP Nontranscribed 
H18 CoG -> AoT 329 CAG TQA ACG Ser -> STOP Nontranscribed 
H16 CoG -> AoT 355 GGT§GA GAT Gly --i STOP Transcribed 
H13 CoG -) AoT 400 GTT§AAGAT Glu -> STOP Transcribed 
H1 CoG --i AoT 580 CTT §AC TAT Asp -> Tyr Transcribed 
H17 CoG -> AoT 589 AAT§AG TAC Glu -> STOP Transcribed 
H23 CoG -> AoT 601 AGG§ATTTG Asp --i Tyr Transcribed 
H21 CoG -> AoT 606 GATTT§AAT Leu --i Phe Transcribed 
H14 CoG -> AoT 634 ACT§GAAAA Gly -> STOP Transcribed 
H19 CoG->GoC 550 ATT QCA GAC Pro -> Ala Nontranscribed 
Strand with 
Mutant Mutation Position 
Surrounding Amino acid affected 
sequencea changed dipyrimidine 
H23 ToA -> AoT 214 GGCIAT AAG Tyr -> Asn Nontranscribed 
H24 ToA --i AoT 389 AAT GIC TTG Val-> Asp Nontranscribed 
H71 ToA --i AoT 389 AAT GIC TTG Val --i Asp Nontranscribed 
H85 ToA -> AoT 437 ACTTIG CTT Leu -> STOP Nontranscribed 
H45 ToA -> AoT 543 GGA TTIGAA Phe --i Leu Nontranscribed 
H76 ToA -> CoG 203 GTG CICAAG Leu -> Pro Nontranscribed 
H90 ToA -> CoG 203 GTG CICAAG Leu -> Pro Nontranscribed 
H53 ToA -> CoG 254 GCA CIG AAT Leu -> Pro Nontranscribed 
H84 ToA -> CoG 392 GTC TIG ATT Leu -> Ser Nontranscribed 
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Strand with 
Mutant Mutation Position 
Surrounding Amino acid affected 
seguencea changed di~yrimidine 
H26 ToA~CoG 404 GAAGATATA Asp ~ Gly Transcribed 
H78 ToA ~ CoG 437 ACTTIG CTT Leu ~ Ser Nontranscribed 
H30 ToA ~ CoG 542 GGA TIT GAA Phe ~ Ser Nontranscribed 
H2 ToA ~ GoC 655 AAA GCCIAA STOP~ Glu Nontranscribed 
Tandem dipyrimidine 
base substitutions 
H81 CoG ~ ToA 112 
CoG ~ ToA 113 
ATT CCT CAT Pro ~ Phe Nontranscribed 
H2O CoG ~ ToA 112 
CoG ~ ToA 113 ATT CCT CAT Pro ~ Phe Nontranscribed 
Nondipyrimidine base 
substitutions 
H7b CoG ~ AoT 617 GTTT§TGTC Cys ~ Phe 
H22b ToA ~ AoT 109 TTT ATT CCT lie ~ Phe 
H27b ToA ~ GoC 584 GAC TAT AAT Tyr ~ Ser 
H91 b ToA ~ GoC 584 GAC TAT AAT Tyr ~ Ser 
Frameshift mutations 
H99 +T 578 - 579 GCC CTT GAC Asp ~ STOP 
H37 -TA 520,521 GGA TAC AGG 
Exon deletions 
H25 Exon 2 
H10 Exon 2 
H8 Exon 2-3 
H60 Exon 2-5 
H68 Exon 2-7 
Deletions 
H11 c 1'.403-456 
H4 c 1'.404-448 
H93 d ~533 - 553 
aSequences of the non-transcribed (coding) strand 
bCcomplex photoproducts have been suggested to occur at ACA and TGT sequences. 
cPresumed cryptic splice acceptor within exon 6 
dpresumed cryptic splice acceptor within exon 8 
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Table 6. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta +/+ Pol 
iota -/- mice. 
Strand with 
Mutant Mutation Position Surrounding 
Amino acid affected 





12 CoG ---> ToA 113 ATT CgT CAT Pro ---> His Nontranscribed 
11 CoG ---> ToA 209 AAG G~G GGC Gly--->Glu Transcribed 
15 CoG ---> ToA 325 GAT gAG TCA Gin ---> STOP Nontranscribed 
142 CoG ---> ToA 463 AGCgCC AAA Pro ---> Ser Nontranscribed 
162 CoG ---> ToA 544 TTT ~AAATT Glu ---> Lys Transcribed 
132 CoG ---> AoT 634 ACT~GAAAA Gly---> STOP Nontranscribed 
Mutations involving 
thymidine 
124 ToA ---> AoT 64 TTG ITTTGT Phe ---> lie Nontranscribed 
128 ToA ---> AoT 64 TTG ITTTGT Phe ---> lie Nontranscribed 
179 ToA ---> AoT 125 CTG AIT ATG lie --->Asn Nontranscribed 
117 ToA ---> AoT 245 TAC AIT AAA lie --->Asn Nontranscribed 
16 ToA ---> AoT 247 AATAAAGCA Lys ---> STOP Transcribed 
Tandem dipyrimidine 
base substitutions 
114 CoG ---> ToA 171 } Met ---> lie 
CoG ---> ToA 172 AT~~GAGGC Gly ---> Arg Transcribed 
122 CoG ---> AoT 112 } Pro ---> lie ATT CCT CAT Nontranscribed CoG ---> ToA 113 Pro ---> lie 
112 ToA ---> AoT 389 } Val---> Asp 
CoG ---> ToA 390 AATGTC TTG Val---> Asp Nontranscribed 
Nontandem double base 
substitutions 
18 CoG --) AoT 589 } Glu ---> STOP 
CoG ---> ToA 591 AAT ~A§. TAC Glu ---> STOP 
191 CoG ---> ToA 599 } Arg ---> Lys 










C-G ~ A-T 




397 ATT 2TT GAA 
482 GTTGgAAGC 
Exon 2-3 
aSequences of the non-transcribed (coding) strand 
bCcomplex photoproducts have been suggested to occur at ACA sequences. 
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Strand with 
Amino acid affected 
changed dipyrimidine 
Val ~ Phe 
Ala ~ Glu 
Table 7. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta -/- Pol 
iota -{- mice. 
Strand with 
Mutant Mutation Position 








HI761 b C-G ---7 T-A 34 AGC§.AT GAT Asp ---7 Asn Transcribed 
HI757 C-G ---7 T-A 325 GATQAGTCA Gin ---7 STOP Nontranscribed 
HI7 C-G ---7 T-A 464 AGC CQCAAA Pro ---7 Leu Nontranscribed 
HI759 b C-G ---7 T-A 493 CTG §.TG AAA Val---7 Met Transcribed 
HI81 C-G ---7 A-T 538 GTT §.GA TTT Gly ---7 STOP Transcribed 
HI61 C-G ---7 A-T 606 GAT TT§. AAT Leu ---7 Phe Transcribed 
HI759 b C-G ---7 A-T 606 GAT TT§. AAT Leu ---7 Phe Transcribed 
HI761 b C-G ---7 A-T 606 GAT TT§. AAT Leu ---7 Phe Transcribed 
Mutations involving 
thymidine 
HI76 T-A ---7 C-G 146 AGA CIlGCT Leu ---7 Pro Nontranscribed 
HI761 b T-A ---7 C-G 203 GTG CIC AAG Leu ---7 Pro Nontranscribed 
HI10 b T-A ---7C-G 194 GCC CICTGT Leu ---7 Pro Nontranscribed 
HI4 T-A ---7 A-T 247 ATT AAA GCA Lys ---7 STOP Transcribed 
HI11 T-A ---7 A-T 543 GGA TTIGAA Phe ---7 Leu Nontranscribed 
HI10 b T-A ---7 A-T 656 GCC TAA GAT STOP ---7 Leu Transcribed 
Tandem dipyrimidine 
base substitutions 
HI63 C-G ---7 T-A 112 } 
113 ATT CCT CAT Pro ---7 Phe Nontranscribed 
Tandem non-
dipyrimidine base 
substitutions } HI86 T-A ---7 G-C 516 AGT GTI§.GA Val---7Val 

















C-G -1 A-T 
C-G -1 T-A 














GAT TAQ ATT 
TTT 8.TT CCT 
GTT AAG CAG 
a Sequences of the nontranscribed (coding strand) 
bMutants containing multiple dimer sites at greater than 150 nucleotides apart 
Amino acid 
changed 
Cys -1 Phe 
Tyr -1 Tyr 
lie -1 Phe 






REV1 INHIBITION REDUCES THE INCIDENCE OF MURINE LUNG 
TUMORS 
SUMMARY 
REV'I is a Y -family polymerase that has catalytic and structural functions 
that implicate it in translesion replication across pre-mutagenic lesions in 
Saccharomyces cere visa e45, mouse93 and human cells 130, The studies covered 
within this chapter test the hypothesis that a reduction in the mutagenic load, 
through REV1 inhibition, will reduce the incidence of cancer. To test this 
hypothesis, vectors that express a ribozyme inhibitory RNA against REV1 were 
created, One vector was designed to target the nucleus (Rz407pU6) and the 
other the cytoplasm (Rz407pN2A). These vectors were complexed with the 
cationic polymer polyethylenimine (PEl) and tested for their ability to reduce 
REV1 mRNA in cell culture. Of the two vectors, the nuclear vector (Rz407pU6) 
clearly showed reduced levels in REV1 mRNA after transfection in NIH 3T3 cells. 
To reduce REV1 in the murine lung the Rz407pU6 vector was delivered via non-
invasive PElf transgene aerosol therapy. This strategy is widely employed as an 
effective non-viral transgene delivery method and is noted as having low 
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cytotoxicity, direct pulmonary transgene delivery, and long transgene expression. 
To determine REV1 mRNA levels in the mouse lung, after PEI/Rz407pU6 
delivery, laser capture microdissection (LCM) was used in conjunction with real-
time RT -PCR. Isolation of bronchial epithelial cells (BEC) from the lung tissue in 
conjunction with real-time RT-PCR indicated REV1 mRNA levels were reduced 
by at least 50% in the bronchial epithelium. 
Ribozyme-mediated REV1 inhibition was used either before or after 
subjecting A/J mice through a carcinogen (B[a]P-induced) lung tumor 
modeI131 ,132" After monitoring the mice for an extended period of time, mice were 
analyzed for tumor burden via micro-positron emission tomography (microPET) 
using the common tracer, [F-18]-fluorodeoxyglucose (FOG). Mice were scanned 
at 12, 16, and 20 weeks with no obvious tumor formation observed. Tumors were 
known to be present in 20 week-old mice by physical dissection and visualization 
of the lung. MicroPET imaging either lacked the resolution or the tumors were not 
metabolically active enough, opposed to surrounding tissue, to support further 
microPET scanning. MicroPET screening was therefore abandoned and tumor 
burden, individual tumor size, and tumor location were elucidated via lung 
dissection after experiment termination, 
After -28 weeks post carcinogen injection, there was a statistically 
significant (p value <.02) reduction in tumor multiplicity in animals that received 
aerosolized PEI/Rz407pU6 complex before carcinogen treatment. This reduction 
was observed only in animals that received Rz407pU6 24 and 48 hours before 
B[a]P injection. Mice receiving the PEIIRz407pU6 complex developed 
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approximately 3.4 tumors per lung compared to approximately 6.4 in mice 
receiving 8[a]P alone. In addition to having a lower tumor multiplicity, REV1 
inhibition prevented tumor formation in 27% of the carcinogen treatment group. 
Tumor size or classification was not affected by treatment. Additionally, when 
REV1 reduction occurred -4 weeks post-carcinogen administration, no 
statistically significant effects in tumor number, size, or mice mortality were 
observed. 
We deduce that the inhibition of tumor development seen with REV1 
inhibition is directly related to a reduction in the total number of mutations 
resulting from REV1-dependant mutagenic bypass of 8[a]P lesions. The data 
presented here collectively support the use of noninvasive aerosolized PEl gene 
therapy and the use of ribozyme inhibitory RNAs in the chemoprevention of lung 
disease. Furthermore these studies show REV1 as having a primary function in 
TLS and indicate targeting mutagenic TLS polymerases can be an effective 
chemoprevention strategy to reduce the incidence of cancer. 
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MATERIALS AND METHODS 
RIBOZYME DESIGN AND RECOMBINANT PLASMID CONSTRUCT 
Hammerhead ribozymes were designed according to established 
structural and sequence principles, maintaining the conserved catalytic core and 
variable target-specific 5'- and 3'-arms 133-135. A GUC cleavage sites at position 
407 on the mouse REV1 mRNA (homologous to position 618 on the human 
REV1 mRNA) was chosen based on potentially accessible loop structures of the 
mouse REV1 mRNA, as modeled with the MFOLD program 136. BLAST search 
determined that the targeted sequence for mouse REV1 around the GUC 
cleavage site has no homology to any other murine REV RNAs and is unique to 
the mouse REV1 target gene (Figure 8). The pLNSX-based retroviral vector 
pN2A-tRNA (gift of Dr. H. Kobayashi, Univ. of Tokyo, Japan) modified with a Pol 
III-tRNA gene ribozyme expression cassette is used for ribozyme expression 
(Figure 9). This promoter system directs the fused tRNA-ribozyme transcripts into 
the cytoplasm, the natural cellular compartment for tRNAs 137-141. Alternatively, 
the ribozyme was cloned into pU6+27 vector containing a human U6 snrp RNA 
promoter/5'··stem-loop/3'-terminator element (gift of Dr. D. Engelke) 142. 
Custom-synthesized DNA oligonucleotides coding for ribozymes were 
annealed and cloned between Sac II and Mlu I sites of the expression cassette in 
pN2A-tRNA and the Sal I and Xba I sites of the expression cassette in pU6+27, 
generating the ribozyme clones Rz407pN2A and Rz407pU6 respectively. Thus, 
the cloned ribozyme inserts are transcribed from the constitutive Pol III tRNA and 
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U6 promoters. The sequences coding for ribozymes were as follows; the 
underlined regions correspond to the catalytic ribozyme core; the bold and italic 
regions to restriction site ends. 
Rz407 pN2A upper strand: 
5'GGTGCAGCCCTGATGAGTCCGTGAGGACGAAACGGCTTGGTGTA3' 
Rz407 pN2A lower strand: 
5' CGCGTACACCAAGCCGTTTCGTCCTCACGGACTCATCAGGGCTGCACCG 
C3' 
Rz407pU6 upper strand: 
5' TCGACTGCAGCCCTGATGAGTCCGTGAGGACGAAACGGCTTGGTGT T 3' 
Rz407pU610wer strand: 
5'CTAGAACACCAAGCCGTTTCGTCCTCACGGACTCATCAGGGCTGCAG3' 
The presence of ribozyme inserts in clones were confirmed by sequencing and 
PCR. Large scale (16L) endotoxin free plasmid production was performed by 
Bayou Biolabs, LA. 
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5' A CAC CAA GCC GUCA GGC UGC A 3' (REV1 mRNA) 










Figure 8. Structure of mouse REV1 ribozyme. Sequence of the target mRNA 
(top sequence) and the catalytically active ribozyme (bottom sequence) are 
shown. The two sequence recognition arms are shown base paired with the 
mouse REV1 target, surrounding the cleavage site at base 407, marked as 0'. 
The central catalytic core is invariant. 
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a. tRNA-Rz cassette 
+1 
b. U6 cassette 
5' stem-loop 3' hairpin 
promoter 
T5 term 
Figure 9. Ribozyme expression cassettes designed to target REV1 mRNA, 
a. tRNA-Rz cassette for cytoplasmic localization, showing the human tRNAMet 
gene with its A- and B-box internal promoters and the Pol III terminator region. 
The ribozyme-coding sequence was inserted at the 3' end upstream of the 
terminator; the entire cassette was inserted into the 3'-L TR of the pN2A retroviral 
vector. b. U6-Rz cassette for nuclear localization, showing the human U6 
promoter, the native 5' and 3' stem-loop structures and the Pol III terminator. The 
ribozyme-coding sequence was inserted between the loop elements, replacing 
the native U6 RNA coding region. 
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PEl-DNA FORMULATIONS 
Polyethylenimine (PEl), high molecular weight (water free), was obtained 
from Sigma-Aldrich (CAS9002-98-6). Stock solutions were prepared at a 
concentration of 4.3 mg/mL in 3xdH20. Experiments were performed to optimize 
the charge ratio expressed as PEl nitrogen:DNA phosphorous (N:P) for the 
Rz407pU6 plasmid. A ratio of 15:1 N:P results in a 1.94:1 (PEI:DNA weight) ratio 
and was used for all in vivo experiments. The desired amount of DNA (2 mg, 
endotoxin free) was mixed in 5 ml of 3xdH20 per nebulization experiment. PEl 
was also mixed with 5 ml 3xdH20. The DNA was slowly added to the PEl 
solution with vigorous vortexing after every 1 ml added. The solution was 
incubated at room temperature for 15 minutes prior to nebulization. 
PElf DNA CELL TRANSFECTIONS 
In vitro assays utilized Opti-MEM@I (GIBCOTM) in lieu of H20 in PElf DNA 
complex preparation. Twenty minutes before transfection 2 I1g of DNA in the 
forms of either gWizTM luciferase [Aldeveron] or plasmid construct Rz407pN2A or 
Rz407pU6 was complexed with PEl as described above in the PEl-DNA 
formulations in 10011 Opti-MEM@1. NIH3T3 cells seeded at a density of 2x1 04 cm2 
in six well plates had their growth media removed and the cells were rinsed in 
sterile PBS (pH 7.4). Appropriate dilutions of PElf DNA complexes was then 
added to each well to allow sufficient coverage. The cells were maintained at 
3rC for at least 24 hours. Opti-MEM@I transfection media was then removed 
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and replaced with normal media for 24hrs before subsequent analysis with a 
luminometer (PharMingen MonolighFM 3010) or real-time RT - PCR. 
JET-PEIIGFP COMPLEX TRANSFECTION 
jetPEITM-FluoR is a tetramethyl rhodamine-conjugated linear 
polyethylenimine derivative (excitation at 555 nm; emission at 580 nm). 
jetPEITM-FluoR is useful for double labelling and colocalization experiments with 
green label using confocal microscopy (ie. green fluorescent protein). We utilized 
this rhodamine-conjugated PEl to deliver PCDNA3 GFP plasmid into NIH3T3 
cells to visualize cellular uptake and location of PEl and GFP. NIH3T3 cells were 
plated in six well dishes at 5 x 105 cells per well. After cells attached ~24 hours 
the media was aspirated and cells washed with sterile PBS (pH 7.4). 4ug of 
PCDNA3 Green Fluorescent Protein (GFP) plasmid was combined with 
JetPEITM-FluoR (Polyplus transfections, France) at varying N:P ratios (ie 10:1, 
20: 1, and 30: 1) diluted in enough Opti-MEM@I transfection media to cover wells 
(~2ml). Control wells received Opti-MEM@I transfection media only, GFP alone or 
JetPEITM. Transfection mixtures were allowed to saturate cells for 24 hours 




Fourteen week old, female A/J mice were used in these studies. Mice 
were obtained from Jackson Laboratories and housed within the Baxter building 
II animal research resource center (RRC). The animals were kept on 12 hr 
day/night cycles and fed normal chow. 
IN VIVO NEBULIZATION 
For exposure to nebulization procedures the mice were housed, five at a 
time, in a 22x9x10cm anesthesia chamber connected to Aero-Mist nebulizer 
(CIS-US Bedford, MA), (Figure 10). Normal air supplemented with 5% CO2 at a 
10 L/ min flow rate (as determined by a flow meter attached to the line connected 
between the air tank and nebulizer) was used to deliver 2 mg of DNA complexed 
with PEl via inhalation. Each treatment took approximately 30 minutes to 
complete. The mice tolerated the treatment well with no obvious signs of stress 
as determined by observing mouse behavior during nebulization. 
CARCINOGENESIS PROCEDURES 
Forty eight hours after first PEl treatment all mice were administered either 
a single bolus dose of 100 mg/ kg of B[a]P carcinogen or cornoil alone by 
intraperitioneal (IP) injection. All mice received by aerosol either, Rz407pU6/PEI 
or PEl (without DNA). Animals were sacrificed -28 weeks post carcinogen 
injection. 
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Figure 10. Mouse nebulization chamber. For exposure to nebulization 
procedures the mice were housed, five at a time, in a 22x9x10cm anesthesia 
chamber connected to Aero-Mist nebulizer (blue top in picture (CIS-US Bedford, 
MA)) Normal air supplemented with 5% C02 was provided at a 10 Llmin flow 
rate. Flow rate was determined by a flow meter attached to the line connected 
between the air tank and nebulizer (black rectangular box with knob). The 
nebulizer contained all PEl/DNA complex solutions. 
76 
HOMOGENATION OF WHOLE LUNG FOR LUCIFERASE AND REV1 
EXPRESSION 
Whole lung protein homogenates were obtained to analyze gWizTM 
luciferase [Aldeveron] expression. For detecting potential strain differences PEl 
mediated transfection in Balb/c verses A/J mice, 2 mg of gWizTM luciferase 
[Aldeveron] was complexed with PEl as indicated in PEl/DNA formulations 
section and delivered with a single treatment to three mice. Mice were sacrificed 
by overdose of ketamine/ xylazine. Mice received .5 ml of 8 mg/ ml ketamine/ 1.2 
mg/ ml xylazine through IP injection. Lung were then dissected and rinsed in 
sterile PBS (pH 7.4) and immersed in RLB lysis solution provided in the Renilla 
Luciferase Assay System with Reporter Lysis Buffer Kit (Promega catalog# 
E4030). Samples were allowed one freeze/ thaw cycle to ensure complete lysis. 
Upon thawing an electric rotor/stator type tissue homogenizer (The Tissue-
Tearor) was used to emulsify the sample. Renilla Luciferase substrate (provided 
in Renilla Luciferase Assay System Kit) was added to each sample and read 
using a luminometer (PharMingen MonolightTM 3010). For the REV1 real-time 
PCR analyses, lungs were dissected and mRNA was extracted using an 
Rneasy® Mini Kit (Qiagen Cat. No. 74104). Samples were disrupted in guanidine 
isothiocyanate lysis buffer (provided in the kit) and homogenized using an electric 
rotor/stator type tissue homogenizer (The Tissue-Tearor). Ethanol was added to 
the lysate and each sample was applied to the Rneasy® mini column before 
centrifugation. RNase-Free DNase Set (Cat. No. 79254) was added to each 
column to ensure complete DNA removal, as required for real-time PCR, before 
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total RNA was extracted in RNase free water. RNA was stored at -80° prior to 
real-time analysis. 
LASER CAPTURE MICRODISSECTION (LCM) 
RNA isolated from whole lung homogenates did not indicate a reduction in 
the levels of REV1 following ribozyme administration as determined by real-time 
RT -PCR. Data however indicates bronchial epithelial cells significantly express 
PElf DNA complexes 143. To isolate these cells form the surrounding tissue we 
utilized Laser Capture Microdissection (LCM) technology. To measure REV1 
levels post Rz407pU6 treatment, lungs were dissected 24hrs after animals 
received 2 mg of the plasmid. Animals were euthanized, lungs removed and flash 
frozen in O.C.T. Compound (Tissue-Tek, Sakura, Torrence, CA) using a 2-
Methylbutane (Sigma-Aldrich CAS 78-78-4) bath suspended in liquid nitrogen. 
The frozen lungs were immediately transported to -80°C in dry ice and sectioned 
in RNase free conditions. Lung sections were stained with HistoGene ™ LCM 
Frozen Section Staining Kit (Arcturus, Mt. View, CA) and -3000 cells were 
captured on a Arcturus Pixcell® lie Laser Capture Microdissection (LCM) System 
(Arcturus, Mt. View, CA) machine using CapSure ™ HS LCM Caps (Arcturus, Mt. 
View, CA). RNA was isolated using PicoPure™ RNA Isolation Kit (Arcturus, Mt. 
View, CA) and stored at -80°C prior to performing real-time RT-PCR. 
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QUANTITATION OF LUNG REV1 MRNA USING REAL-TIME RT-PCR 
Real-time quantitative RT -PCR was performed using ABI PRISM 7900 
Sequence Detection System (Applied Biosystems AB, Foster City, CA) using 
TagMan Universal PCR Mix (Applied Biosystems, Foster City, CA); a gene 
specific MGB TaqMan Probe (Applied Biosystems); mouse REV1 primers; 
TaqMan Rodent GAPDH Control reagents (Rodent GAPDH internal control 
Probe, forward and reverse primers; Applied Biosystems) The TaqMan gene-
specific probe and primers were designed using the ABI Prism Primer Express 
Software Version 1.5 (Applied Biosystems, Foster City, CA) The sequence of the 
mouse REV1 primers are as follows: 
mREV1 Frt (forward) - 5'CCGGGAGTTGGACGTTCA3'; 
mREV1 Rrt (reverse)- 5'GCAAATCTCCACAAGTCTTAATCC3'; 
The sequence of the mREV1 TaqMan Probe is as follows: 
6FAM-AGCTTGCATCTTCG-MG BNFQ 
Relative amounts of target RNA for duplicate sample runs were quantitated 
with the instrument software and normalized to the corresponding GAPDH 
values. Fold change values were calculated using the comparative CT method (2· 
CT) 144. 
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MICRO-POSITRON EMISSION TOMOGRAPHY (MICROPET) 
Micro-positron emission tomography (microPET) was used in these 
studies to visualize lung tumor development in mice. The microPET scans were 
performed at the James Graham Brown Cancer Center (JGBCC) utilizing a paid 
service. Mice were fasted for 16 hours prior to microPET. These animals were 
then transported from the Baxter II animal research resource center (RRC) to the 
JGBCC where the imaging took place. Mice were scanned at 12, 16, and 20 
weeks, using the common tracer, [F-1S]-fluorodeoxyglucose (FOG). Following 
scans mice were given normal chow and housed at the JGBCC for 24 hours 
before returning to the Baxter II animal facility. 
TUMOR BURDEN/ HISTOLOGY 
To determine tumor burden, lungs from sacrificed animals were placed in 
Tellyesniczky's Solution (90% ethanol, 5% formalin <10%>, and 5% acetic acid) 
for 24 hours followed by immersion in 70% ethanol for a minimum of 24 hours. 
Individual lobes of the lungs were separately dissected and gross tumors counts 
were performed on the surface of each lobe using a light box. Pathology was 




Statistical analyses consisted of a negative binomial regression and 
planned post hoc comparisons between individual groups for tumor multiplicity 
count data. One-way ANOVA and t-tests between individual groups were used 




OPTIMIZATION OF PEl-REPORTER GENES AND PEI-RIBOZYME 
TRANSFECTION IN NIH3T3 CELLS. 
The N:P ratio (PEl nitrogen:DNA phosphorous) has a significant impact on 
transfection efficiency and must be optimized. We used a reporter gene gWizTM 
luciferase [Aldeveron] and the Rz407pU6 and Rz407pN2A constructs to verify 
expression of plasm ids constructs, optimization of N:P (PEl nitrogen:DNA 
phosphorous) ratios, and verify inhibition of REV1 in both NIH3T3 cells and the 
murine lung. 
The greatest expression was observed in NIH3T3 cells receiving PEI/ 
gWizTM luciferase (PEI/Luc) at a N:P ratio of 20: 1 illustrated (Figure 11). 
However, when the same cell line was exposed to PEI-Rz407pU6 (2 ~g of 2.9 kb 
plasmid) complex at varying N:P ratios (10:1, 20:1, 30:1) the largest reduction in 
REV1 mRNA was observed using a 10:1 N:P ratio (Figure 12). Delivery of both 
plasm ids Rz407pU6 and Rz407pN2A in NIH 3T3 cells showed no additive effect. 
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Figure 11. Luciferase expression in NIH3T3 cells following PElf LUC 
transfection. NIH3T3 cells seeded at a density of 2x104 cm2 in six well plates 
had their growth media removed and the cells were rinsed in sterile PBS (pH 
7.4). Appropriate dilutions of PElf Luciferase complex was then added to each 
well to allow sufficient coverage. The cells were maintained at 3rC for at least 
24 hours before lysis and analysis using a luminometer. Graph illustrates 
significant luciferse expression in NIH3T3 using 5-25:1 N:P ratios. 
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Figure 12. Analysis of REV1 mRNA inhibition in NIH 3T3 cells by real-time 
RT peR after PElf Rz407pU6 transfection. NIH3T3 cells seeded at a density of 
2x104 cells/ cm2 in six well plates had their growth media removed and the cells 
were rinsed in sterile PBS (pH 7.4). Appropriate dilutions of PEI/ Rz407pU6 
complex were added to each well. Real-time RT peR analysis occurred after 24 
hours. REV1 inhibition was most significant with the Rz407pU6 plasmid using a 
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Figure 13. Analysis of REV1 mRNA inhibition in NIH 3T3 cells by real-time 
RT peR after PElf Rz407pU6 and Rz407pN2A transfection. NIH3T3 cells 
seeded at a density of 2x104 cells/ cm2 in six well plates had their growth media 
removed and the cells were rinsed in sterile PBS (pH 7.4). Appropriate dilutions 
of PEI/ Rz407pU6 complex were added to each well. Real-time PCR analysis 
occurred after 24 hours. 
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VISUALIZATION OF JET-PEl AND GREEN FLOURESCENT PROTEIN IN 
MURINE NIH3T3 CELLS. 
NIH 3T3 cells were treated with jetPEITM-FluoR / PCDNA3 GFP 
complexes in six well dishes. Transfection mixtures were allowed to saturate 
cells for 24 hours before visualization on fluorescent microscope outfitted with 
standard optical filter sets. Control cells transfected with jetPEITM-FluoR only 
showed high cellular uptake of jetPEITM-FluoR (data not shown), while GFP only 
did not transfect. Cells treated with the jetPEITM-FluoR / PCDNA3 GFP complex 
showed broad cellular distribution of jetPEITM-FluoR (Figure 14, red) and 
expression of GFP reporter plasmid in smaller foci (Figure 14, green). 
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Figure 14. Visualization of jetPEITM-FluoR and PCDNA3-GFP in NIH3T3 
cells. NIH 3T3 cells were treated with jetPEITM-FluoR / PCDNA3 GFP complexes 
in six well dishes. Transfection mixtures were allowed to saturate cells for 24 
hours before visualization on fluorescent microscope outfitted with standard 
optical filter sets. Cells treated with the jetPEITM-FluoR / PCDNA3 GFP complex 
showed broad cellular distribution of jetPEITM-FluoR (red) and expression of GFP 
reporter plasmid in smaller foci plasmid (green). 
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OPTIMIZATION OF PEI/ LUC TRANSFECTION IN LUNG TISSUE. 
In vivo delivery of luciferase reporter gene was used to detect possible 
strain differences in Balb/c versus A/J mice in PEl mediated gene delivery. 
PEI/Luc was administered (based on the PEI/Luc N:P ratios established in cell 
culture) at a N:P ratio of 15:1. 2mg of the reporter gene gWizTM luciferase 
[Aldeveron] was delivered in thirty minutes. Lungs were dissected 24-48 hours 
later and analyzed for luciferase expression (Figure 15). The highest expression 
occurred in Balb/c mice though there was significant expression in both strains. 
Collagenase was added in an attempt to reduce the total sample homogenation 
time for one sample set. The additional treatment of lungs in the homogenation 
step with collagenase, adversely effected the overall detection of luciferase 
(Figure 15, column 3 and 4) and was discontinued. Based on these experiments 
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Figure 15. Luciferase expression in the lung. PEI/Luc was administered at a 
N:P ratio of 15: 1 using 2 mg of the reporter gene gWizTM luciferase [Aldeveron]. 
Graph represents relative light units (RLU)/ mg of lung protein 24-48 hours after 
transfection. Columns 3 and 4 show the decrease in RLU detection as result of 
the addition of collagenase before lysis. 
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LASER CAPTURE MICRODISSECTION 
Mice were exposed twice to two milligram aerosolized doses of ribozyme 
plasmid Rz407pU6 complexed with PEl (15:1 N:P ratio) or PEl aerosol alone for 
30 minutes in a whole body exposure chamber. Using laser capture micro-
dissection it was possible to isolate only the bronchial epithelium in order to 
determine the expression of REV1. Figure 16 a shows a representative lung 
section as stained via Arcturus protocol before isolation. The subsequent picture 
Figure 16b shows the cap as it was isolated. The remaining photo Figure 16c 
shows the tissue after the cap was removed. LCM bronchial epithelium was 
examined after RNA isolation from -3000 cells using real-time RT -PCR. 
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16a) 16b) 16c) 
Figure 16a-c. Laser Capture Microdissection of Rz404pU6 treated lungs. 
Lungs were dissected from the mice and flash frozen. Frozen lungs were 
immediately transported to -80 DC in dry ice and sectioned in RNase free 
conditions. Lung sections were stained with HistoGene ™ LCM Frozen Section 
Staining Kit (Arcturus, Mt. View, CA) and cells captured on a Arcturus Pixcell® lie 
Laser Capture Microdissection (LCM) System (Arcturus, Mt. View, CA) machine 
using CapSure™ HS LCM Caps (Arcturus, Mt. View, CA). RNA was isolated 
using PicoPure™ RNA Isolation Kit (Arcturus, Mt. View, CA) and stored at -80 DC 
prior to performing real-time RT -PCR. 16a) 10x picture before capture. 16b) 10x 
picture of cells captured on cap. 16c) 10x picture of tissue after removal of 
capture cells. 
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REV1 EXPRESSION IN MOUSE LUNG FOLLOWING AEROSOL DELIVERY OF 
PElf RZ407PU6 COMPLEXES. 
LCM allowed the isolation of bronchial epithelium tissue. This tissue was 
analyzed for REV1 transcript levels via real-time RT -PCR as described in the 
Materials and Methods section. These mice were taken in an unbiased manner 
48 hours after treatment with Rz407pU6. Data in Figure 17 summarizes 3 
independent real-Time RT-PCR experiments from two mice. Column 4 is the 
average of the two treated mice. The treatment of RZ407pU6 lead to an 







Figure 17. Inhibition of REV1 in the mouse lung. Graph represents a 
summary of 3 independent real-time RT-peR experiments from two mice. Last 
bar is the average of the two treated mice. The treatment of RZ407pU6 lead to 
an approximate 50% decrease in REV1 transcript. 
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MICRO-POSITRON EMISSION TOMOGRAPHY (microPET) 
The microPET scans of mice at 12, 16, and 20 weeks post-carcinogen 
injection were analyzed with the microPET manufacturers software. No lung 
tumors were visualized at any of the time points (12,16, or 20 weeks). During the 
20 week scans, two 8[a]P treated mice developed large site of injection tumors 
and had to be sacrificed. Upon visual inspection of the lungs, multiple >1 mm 
tumors had arisen. MicroPET imaging was therefore determined inadequate in 
detecting 8[a]P induced adenomas and was abandoned. Figure 18 illustrates a 
snap shot of a scan at 16 weeks. 
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Figure 18. Micro-positron emission tomography (microPET). MicroPET 
scans were performed at the James Graham Brown Cancer Center (JGBCC) in 
collaboration with Dr. Chin Ng. Mouse pictured above was scanned at 16 weeks 
after B[a]P injection and PEI/Rz407pU6 complex inhalation using the common 
tracer, [F-18]-fluorodeoxyglucose (FOG). MicroPET imaging showed no 
indication of lung tumors. 
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INHIBITION OF LUNG TUMOR MULTIPLICITY AFTER AEROSOL DELIVERY 
OF PEI-RIBOZYME COMPLEXES. 
We tested the efficacy of aerosol delivery of PEI- Rz407pU6 in the 
formation of B[a]P induced lung tumors in female A/J mice. Mice were exposed 
to 2mg of Rz407pU6 plasmid or control, 48 and 24hrs before treatment with 
100mg/ kg B[a]P. After -28 weeks post carcinogen the mice were sacrificed, 
lungs fixed, and tumor multiplicity and size recorded. Mice receiving B[a]P alone 
developed about 6.4 individual tumors per mouse (Figure 20, column 3). This 
was reduced to 3.4 tumors per lung (Figure 20, column 5) in mice receiving 
Rz407pU6. Statistical significance was reached using analysis that included 
negative binomial regression and planned post hoc comparisons between 
individual groups (p value <.02). 
The female A/J mice used in these studies developed 0.5 spontaneous 
tumors per mouse (Figure 20, Column 1). Mice treated only with ribozyme 
developed .39 tumors per mouse (Figure 20, Column 2). The differences in 
spontaneous tumor burden between mice receiving PEl/corn oil alone and mice 
receiving cornoil plus Rz407pU6 did not reach statistical significance. 
Treatment with PElf Rz407pU6 prevented the formation of tumors in 27% 
of the mice (Table 8, column 2). There was no apparent effect on which lobe 
tumors developed (Table 8). There was no increase or decrease in multiplicity or 
size when the PEI/ Rz407pU6 was given post carcinogen treatment when 
compared to carcinogen alone (Figure 19, compare columns 4 and 5). As 
expected, there remained a significant (p <.02) difference in tumor multiplicity 
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between treatment with PElf Rz407pU6 before 8[a]P administration and PElf 
Rz407pU6 nebulization followed by 8[a]P. Individual tumor sizes are plotted in 
Figure 20. There was no statistically significant difference between groups as 
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Figure 19. Scatter plot of number of tumors that developed in female AlJ 
mice. To determine tumor burden, lungs from sacrificed animals were placed in 
Tellyesniczky's Solution for 24 hours followed by emersion in 70% ethanol for a 
minimum of 24 hours. Individual lobes of the lungs were separately dissected 
and gross tumors counts were performed on the surface of each lobe using a 
light box. Graph represents the number of tumors per mouse for each group. 
8[a]P/ Ribozyme represents 8[a]P injection before Rz407pU6 was administered 
(4 weeks post-carcinogen injection). Ribozyme/ 8[a]P represents treatment with 
Rz407pU6 24 and 48 hours before 8[a]P injection. Mice receiving 8[a]P alone 
developed about 6.4 individual tumors per mouse (Table 20, column 3). This was 
reduced to 3.4 tumors per lung (Table 20, Column 5) in mice receiving 
Rz407pU6. Statistical significance (p value= .02) was reached using negative 
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Figure 20. Scatter plot of individual tumor size. To determine individual tumor 
size, lungs from sacrificed animals were placed in Tellyesniczky's Solution for 24 
hours followed by emersion in 70% ethanol for a minimum of 24 hours. Individual 
lobes of the lungs were separately dissected and gross tumors counts were 
performed on the surface of each lobe using a light box. Graph represents the 
individual tumor size of all mice for each group. 8[a]P/ Ribozyme represents 
8[a]P injection before Rz407pU6 was administerd (4 weeks post-carcinogen). 
Ribozyme/ 8[a]P represents treatment with Rz407pU6 24 and 48 hours before 
8[a]P injection. There were no statistically significant differences between groups 
as determined by one-way ANOVA and t-tests between individual groups. 
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Table 8. Summar~ of tumor develoement 
% of Total tumors in each lobel total tumors 
No. of mice 
surviving with Left Caudal Cranial Middle Accessory 
Group mice tumors Lung Lobe Lobe Lobe Lobe 
Control 12 42 50% 17% 0% 33% 0% 
Rz407pU6 13 31 60% 20% 20% 0% 0% 
B[a]P 12 100 38% 25% 17% 16% 4% 
B[a]p+Rz407pU6 14 100 3Ei% 28% 11% 14% 11% 
Rz407pU6+B[a]p 15 73 43% 30% 11% 2% 15% 
Table 8. Summary of lung tumor development. To determine tumor 
development, lungs from sacrificed animals were placed in Tellyesniczky's 
Solution for 24 hours followed by emersion in 70% ethanol for a minimum of 24 
hours. Individual lobes of the lungs were separately dissected and gross tumors 
were measured on the surface of each lobe using a light box and ruler. Total 
tumors in each lobe for all groups reflected relative lobe size. The largest lobe is 
the left lung and contained the majority of tumors for each group. The caudal 
lobe second largest lobe and contained fewer tumors compared to the left lung 
but more than the remaining lobes. Relative tumor numbers in remaining lobes 
(cranial, middle, and accessory) were minimal. 
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TUMOR HISTOLOGY 
Tumors from each treatment group were dissected from mice in each 
treatment group. Tumors were paraffin embedded and serial sectioned. Serial 
sections were treated with haematoxylin and eosin (H&E) stain. Sections were 
analyzed under a 10x microscope for differences in tumor histology. Mice in all 
five groups showed hyperplasia (Figure 21), and homogeneous spherical 
masses (Figure 21) that mayor may not have compressed surrounding lung 
parenchyma, classified by A. Bennett Jenson, M.D. (Professor, Laboratory of 
Vaccinology, James Graham Brown Cancer Center) as adenoma (Figure 22). 
There was no histological evidence of metastasis (Figure 23). 
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Figure 21. Hyperplasia! small adenoma formation in the murine lung. Lungs 
from sacrificed animals were placed in Tellyesniczky's Solution for 24 hours 
followed by emersion in 70% ethanol for a minimum of 24 hours. Lungs were 
paraffin embedded and sectioned at 8 j..lm. Sections were stained with 
haematoxylin and eosin (H&E) stain and analyzed on a microscope fitted with a 
camera. Tumors from all groups exhibited the same morphology. Pictured above 
is severe hyperplasia/ small adenoma formation as viewed at 10x. 
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Figure 22. Adenoma formation in the murine lung. Lungs from sacrificed 
animals were placed in Tellyesniczky's Solution for 24 hours followed by 
emersion in 70% ethanol for a minimum of 24 hours. Lungs were paraffin 
embedded and sectioned at 811m. Sections were stained with haematoxylin and 
eosin (H&E) stain and analyzed on a microscope fitted with a camera. Tumors 
from all groups exhibited the same morphology. Pictured above is an adenoma 
as viewed at 1 Ox. 
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Figure 23. Massive adenoma formation in the murine lung.. Lungs from 
sacrificed animals were placed in Tellyesniczky's Solution for 24 hours followed 
by emersion in 70% ethanol for a minimum of 24 hours. Lungs were paraffin 
embedded and sectioned at 811m. Sections were stained with haematoxylin and 
eosin (H&E) stain and analyzed on a microscope fitted with a camera. Tumors 
from all groups exhibited the same morphology. Pictured above is a massive 
adenoma as viewed at 10x. 
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DISCUSSION 
REV1 is an integral component of the lesion bypass machinery required 
for bypass of replication blocking lesions. The metabolism of ubiquitous 
environmental carcinogen B[a]P (Figure 2a) leads to many DNA reactive 
intermediates that form such helix perturbing lesions. 
Of particular historical importance, is the presumable ultimate carcinogen 
(±)- 7f3, 80- dihydroxy 90, 100 -epoxy- 7, 8, 9, 10 tetrehyrobenzo[o]pyrene 
(BPDE) which is implicated as the primary metabolite responsible for the majority 
of mutations induced by TLS145 (Figure 2b).The specific effect of targeting certain 
TLS polymerases, including REV1, to reduce error prone bypass of lesions such 
as that produced by B[a]P, is currently a topic of great research interest. 
We hypothesize that by selectively inhibiting REV1 in the murine lung we 
would reduce the formation of mutations resulting from B[a]P exposure. This 
would effectively inhibit or reduce the initiation phase of carcinogenesis leading 
to tumor development. Although knock out mice exist for REV1, the genotype 
results in strain-specific effects on embryonic lethality. Survivable strains exhibit 
transiently reduced weight with no other obvious abnormalities. These data 
suggest that REV1 may function in a strain-dependant fashion in regards to 
endogenous DNA damage 146. It currently unknown is unknown if REV1 has 
additional functions in addition to its role in TLS. Based on the similarity between 
data derived from yeast and higher eukaryotes, we hypothesized REV1 reduction 
would inhibit mutagenesis and effectively be observable as a reduction in tumor 
formation. 
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GENE DELIVERY VIA PElf DNA AEROSOL INHALATION 
Polyethylenimine (PEl) mediate gene therapy is an attractive means to 
deliver a variety of transgene products to the lung 147,148. One major use of the 
cationic polymer PEl is to complex it with DNA and aerosolizing the mixture to 
deliver transgenes to the lung 149. PEl gene delivery is noted for not inducing 
many cellular protective responses 150,151 that are seen with transgenes delivered 
via viruses. PEl holds therapeutic promise in many pulmonary diseases that are 
sensitive to exogenous particles and viruses. One important consideration 
supporting PEl gene therapy in carcinogen-induced mouse models is that it does 
not appear to be inflammatory to the murine lung 152,153. This feature is noteworthy 
since inflammation promotion using BHT has been shown to increase both tumor 
multiplicity and size in B[a]P induced tumors 154. PEl based gene delivery to the 
lung has been shown to be successful in multiple animal models of human 
disease and recently used to re-establishing p53 status and eradicating 
metastasis of lung cancers in miceI55-158. Because of these studies, the use of 
non-viral gene delivery is currently gaining promise in the fields of gene 
therap/59 and was used in these studies to aid in the delivery of the REV1 
targeting ribozyme plasmid Rz406Pu6. 
We utilized the whole body exposure approach to deliver aerosolized PElf 
DNA complexes to the murine lung. This exposure method remains a fast reliable 
method to deliver and sustain transgene expression in the lung 160. REV1 levels 
are cell-cycle dependant and speculate that REV1 inhibition through PEl delivery 
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would be present weeks after inhalation 161. We found significant in vivo and in 
vitro luciferase expression with PEI/luc 48 hours after treatment using the whole 
animal approach with varying N:P ratios (Figure 11). The ratio of N:P is critical 
and has a significant effect on transfection efficiency and must be optimized. 
While the importance of N:P optimization to get transgenes into the cytoplasm 
cannot be understated, it is notable that the plasmid compaction of DNA rather 
than the N:P ratio is primarily responsible for transgene trafficking to the 
nucleus 162. Significant expression using PEI/ luc in vitro occurred when Llsing a 
range from 15:1 to 25:1 N:P ratio (Figure 11). When the same techniques were 
applied in vivo with Rz107pU6 a ratio of 10: 1 was optimal (Figure 15). Based on 
these differences a 15: 1 ratio was used for nubilization experiments and was 
found to be effective. Our studies confirm PEl/DNA treatment was well tolerated 
in the mouse and is not cytotoxic at the dose and exposure time uSBd cell 
culture. 
Initial experiments (data not shown), using electroporation, indicated both 
Rz407pU6 and Rz407pN2A as very effective antiREV1 constructs, consistently 
lowering transcript up to ~80% in vitro. However when complexed with PEl 
transfected into NIH 3T3 cells, Rz407pU6 and not Rz407pN2A was found to 
reduce REV1 mRNA transcript (Figure 13). Rz407pN2A did not lower REV1 
mRNA transcript (Figure 13). Rz407pN2A is a much larger plasmid (10.1 kb) 
compared to Rz407pU6 (2.9 kb) perhaps explaining lack of REV1 inhibition and 
its use in subsequent experiments was discontinued. 
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REV1 INHIBITION IN THE MURINE LUNG 
To determine reduction of REV1 mRNA in the murine lung we treated 
mice with aerosolized PEIIRz407pU6 and analyzed whole lung homogenate for 
REV1 expression via real-time PCR. Not surprisingly, due to the vast size and 
diverse cell types, we observed no reduction in REV1 when analyzing total lung 
mRNA. We demeaned this methodology inappropriate since PEl has been 
shown to mediate significant expression of plasm ids across certain regions but 
not necessarily the entire lung. However using LCM we were able to obtain cells 
from the bronchial epithelium and analyze REV1 (Figures 16 and 17). This tissue 
has been reported to not only significantly express plasmids delivered with 
aerosolized PEl/DNA but has also been elucidated as the region harboring 
bronchioalveolar stem cells (BASC) responsible for adenocarcinomas 143,163. The 
studies here report here a reduction in REV1 mRNA transcript by 50%, using 4 
~g of Rz407pU6 delivered over 2 x 30min exposures (Figure 17). Together these 
data support the use of PEI/ DNA based aerosol therapy as a safe and effective 
method to deliver genes to bronchial epithelium. The reduction in REV1 mRNA 
after Rz407pU6 transgene expression in the lung also supports the use of 
hammerhead ribozymes as an effective method to consistently knockdown 
REV1. 
MICRO-POSITRON EMISSION TOMOGRAPHY (MICROPET) 
Mice were scanned at 12, 16, and 20 weeks, using the common tracer, [F-
18]-fluorodeoxyglucose (FOG). Scans were analyzed with micro PET 
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manufacturers software (Figure 18). Unfortunately, no tumors were visible at any 
of the time points. The most logical reason as to why lung tumors not were 
visualized may be explained by either lack of resolution in the microPET pet 
imaging system or lack of FOG uptake by the tumors. While the microPet 
imaging personnel indicated that tumors approximately 0.8mm in diameter are 
visible by microPET, the actual uptake of FOG by the tumor and surrounding 
tissue may impact this resolution. The background levels of FOG in the lung 
appeared to be relatively minor. Thus, either the resolution of microPET is less 
than indicated or the tumors in the lung absorbed FOG at approximately the 
same levels as the surrounding tissue. 
REV1 REDUCTION DECREASES TUMOR MULTIPLICITY IN THE MURINE 
LUNG 
Effects of targeting certain translesion synthesis polymerases to inhibit 
cancer formation remains unclear, particularly as shown in Chapter II with the 
inhibition of pol iota 164. TLS however is recognized as an important mechanism of 
action in the formation of mutations that eventually lead to tumor development164 . 
This hypothesis of inhibiting cancer by lowering the cells ability to erroneously 
bypass DNA lesions is supported in these studies. 
We report here that the use of plasmid encoding a ribozyme inhibitory 
RNA (Rz407pU6) complexed with PEl and delivered to the lung before B[a]P 
injection decreased lung tumor multiplicity from an average of 6.4 tumors/ mouse 
to 3.7 tumors/ mouse (p value=.02) (Figure 19). There was also a reduction in the 
109 
total number of mice that developed tumors from 100% to 73% (Table 8). Our 
data suggests tumor inhibition by REV1 is primarily due to the reduction in 
mutations formed through the TLS pathway. Thus, tumor inhibition by these 
mechanisms is chemopreventive and requires the therapy to be initiated before 
DNA adducts are replicated. These data presented here are consistent with 
inhibition of initiation rather than a delay in progression. This conclusion is 
supported by observations that there were no significant differences in tumor 
size, the tumors were histologically similar (Figures 21-23), and 4 of 15 surviving 
mice did not develop tumors (Table 8). 
The question remained what effect, if any, on tumor development would 
be observed when this REV1 inhibition occurred after the majority of adducts 
were cleared. To address this we included one treatment group given Rz407pU6 
-4weeks post carcinogen. As expected, there were no differences in mouse 
mortality or tumor development and morphology. These data suggest 
noninvasive REV1 inhibition may still be used in tissue previously exposed to a 
carcinogen with no ill effects and support REV1 inhibition as a useful strategy in 
the chemoprevention of lung cancer. 
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TUMOR HISTOLOGY 
Tumors from each treatment group were dissected from mice in each 
treatment. Tumors were paraffin embedded and serial sectioned. Serial sections 
were treated with haematoxylin and eosin (H&E) stain. Sections were analyzed 
under a 10x microscope for differences in tumor morphology. Mice in all five 
groups showed hyperplasia occurring around the bronchial epithelium (Figure 
21). Homogeneous spherical masses were also observed in all groups and these 
masses mayor may not have compressed surrounding lung parenchyma, 
classified as adenoma (Figure 22). Additionally, extremely large adenomas with 
no apparent loss of border or metastasis were observed in all groups (Figure 23). 
These results indicated that Rz406pU6 had no observable effects the types of 





The data presented in this dissertation provide insights into the 
mechanisms used by higher eukaryotic cells to complete the replication of 
genomes that enter S-phase with residual, unrepaired DNA damage. These 
mechanisms have been conserved from prokaryotes to eukaryotes, including 
plants and post-mitotic organisms such as O. me/anogater and C. e/egans. The 
ubiquitous nature of DNA damage tolerance pathways attests to their importance 
in genome maintenance. The molecular details surrounding these pathways are 
only now being elucidated, and the most intensively studied organisms are E. coli 
amongst the prokaryotes and S. cerevisiae amongst the eukaryotes. The 
increased complexity of damage tolerance pathways in higher eukaryotes, in 
particular the presence of a number of polymerases that are not found in lower 
organisms, has obscured the molecular mechanisms involved. Of particular 
interest in this regard are the events surrounding the switch from replicative to Y-
family DNA polymerases and the factors that govern which of the universe of 
pOlymerases is to be employed when the replicative complex is stalled at a 
particular lesion. One notion in the literature supposes that polymerases are 
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specialized for bypass of particular lesions. This arose from in vitro data using 
purified polymerases in the absence of accessory proteins, such as PCNA. 
These data indicate that pol eta bypasses T-T CPO with the preferential insertion 
of A-A across form the lesion, thereby being error-free. Teleologically, this 
specialization is supported by the fact that the UV component of sunlight is the 
most ubiquitous carcinogen to which organisms are exposed, and T-T CPO are 
the most common photoproduct. If true, then are other polymerases specialized 
for other adducts, such as those induced by chemical carcinogens? It is difficult 
to imagine how a stalled polymerase complex would differentiate between one 
helix-distorting lesion and another. An alternative possibility, which is not 
necessarily mutually exclusive with the lesion-specific idea, is that there is a 
hierarchy of polymerases. My approach to begin to address the issue of the 
events surrounding polymerase switching in higher eukaryotic cells was to 
examine the mutagenic phenotype of cells derived from mice with combinatorial 
deficiencies in pol eta and/or pol iota. Importantly, the development of these 
mouse models allows us to examine the relationship between mutagenesis and 
carcinogenesis in a detailed manner. 
The discovery in 1999 of DNA polymerase eta and its deficiency as the 
molecular defect underlying the skin cancer-prone XP variant syndrome was a 
major development on the field of mutagenesis. This immediately led to an 
intensive international effort to develop a knockout mouse. However, many 
attempts to accomplish this resulted in embryonic lethality, a result that remains 
puzzling even now since lethality does not accompany biallelic deficiency in 
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human cells. Parenthetically, it is speculated that disruption of a large genomic 
region surrounding the pol eta gene disrupts another gene required for 
development. Fortunately, Dr. Kunkel and Dr. Kucherlapati were able to devise a 
strategy to ablate the polymerase domain with minimal disruption to the genomic 
structure surrounding the gene. The mutagenesis studies reported in this 
dissertation were derived, in part, from these mice. I found that these cells 
recapitulate the UV sensitivity of human XP variant cells to a remarkable extent. 
For instance, the 0 37 of murine cells deficient in pol eta is - 3 J/m
2
, which 
compares favorably with the reported value of 3.8 J/ m2 in XP variant cells. More 
importantly, the murine cells are extraordinarily hypermutable with respect to UV. 
The frequency of mutations at every UV fluence examined was several fold 
higher than that observed in wild-type cells. Further, examination of the 
spectrum of mutations indicated that most of the mutations arose from putative 
photoproducts in the leading strand template, and there was a very high 
proportion of CG to AT transversions, all of which arose from this strand. This 
spectrum is very similar to that found in XP variant cells, and confirm the 
hypothesis that pol eta preferentially acts on the leading strand template. In its 
absence, another, more error-prone enzyme assumes this function resulting in 
hypermutability. Carcinogenesis studies with these mice resulted in an 
accelerated UV-induced skin cancer phenotype, as expected from the 
hypermutability of the cells derived from these mice and in accord with the 
clinical observations in XP variant patients. 
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In contrast to the phenotype of the pol eta-deficient mice, pol iota 
deficiency resulted in greatly reduced mutant frequency compared to wild-type 
cells. Examination of the mutation spectrum derived from these mice showed that 
there were no differences in the kinds of mutations induced by UV, but the 
frequency of mutations arising from photoproducts in the lagging strand template 
was greatly reduced. The importance of these findings is that this is the first clear 
demonstration that pol iota has a biological function, performing error-prone 
bypass of UV photoproducts in vivo. Further, data support a model in which pol 
eta primarily acts on the leading strand template at the same time that pol iota 
acts on the lagging strand. The function of pol iota becomes even more apparent 
when pol eta is also absent, as in the double knockout. In this case, the extreme 
hypermutability resulting from the pol eta deficiency is reduced essentially to wild 
type levels. The pol iota deficiency in this background reduces mutations arising 
from photoproducts in both strands, but has a proportionally greater effect on 
those in the lagging strand template. These data support the conclusion that pol 
iota is the principal TLS polymerase in the absence of pol eta. Further, a third 
polymerase is able to conduct mutagenic photoproduct bypass, since the mutant 
frequency in the double knockout is reduced but not to zero. It can be 
speculated that this polymerase may be pol kappa, and suggests that the 
preferred hierarchy is pol eta > pol iota > pol kappa, at least for UV 
photoproducts. 
There is a large body of data to support the hypothesis that cancer 
results from the accumulation of mutations in critical growth-control genes. 
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Therefore, the greatly reduced frequency of mutations in the cells derived form 
the double knockout mice would predict that these mice would develop skin 
cancer with a much greater latency than the pol eta (XP variant) mice. 
Unexpectedly, however, the former mice developed squamous cell skin cancer 
with a greatly decreased latency, which was highly statistically significant. The 
reasons for this are speculative and form the basis of future studies. 
The simplest of explanations would be that mutagenesis at the Hprt locus in 
primary fibroblasts does not reflect mutations in the cell types and/or genes most 
relevant to development of skin tumors in mice. Opposition to this hypothesis is 
supported by measurements of mutagenesis at the Hprt locus in pol eta-deficient 
XP variant fibroblasts that do correlate with elevated susceptibility to skin cancer. 
Despite this evidence, it would be possible to further test against Hprt criticism 
through the isolation of keratinocytes, the cell type of tumor origin, and 
comparatively sequence key genes such as p53 and check for mutation 
spectrum differences. 
Another possibility is that pol iota may play an important role in the 
development of normal immunity, such that a deficiency in pol iota would 
compromise immune suppression of skin cancer and lead to increased 
susceptibility. This possibility is unlikely due to reports of normal class switch 
recombination and somatic hypermutation of immunoglobulin genes in 129-
derived strains of mice, many substrains of which have a naturally occurring 
deficiency of pol iota. However these studies were not completed during UV-
irradiation and may not rule out the possibility that difference in immune 
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suppression may remain. Thus, inflammation may still playa large part in the 
observed difference in tumor formation and would have to be tested as the 
animals were being exposed to UV-light. 
Another possibility, and the one I favor, is the idea that pol iota has 
multiple cellular roles and modulates cancer susceptibility. One role that can be 
experimentally tested is that pol iota is involved in cell cycle checkpoint 
responses to DNA damage. For instance, it has been known for some time that 
the mouse pol iota gene is on chromosome 18 and within the Par2 (pulmonary 
adenoma resistance 2) locus. This is a major determinant of susceptibility to 
urethane-induced pulmonary adenomas. A defective pol iota allele in the 
129X 1 ISv mouse strain has been shown to be associated with increased 
susceptibility to urethane-induced lung tumors. The possibility of additional roles 
for pol iota remains and is currently under active investigation. 
In Chapter III the well-established TLS polymerase REV1 was targeted in 
an attempt to lower the incidence of B[a]P induced murine lung tumors. These 
studies were based on earlier observations from the McGregor laboratory that 
ribozyme-mediated REV1 inhibition reduced BPDE-induced mutation in cell 
culture. In these studies endogenous REV1 mRNA in the lung was effectively 
lowered with the use of novel treatments. These treatments included the use of a 
REV1 mRNA targeting hammerhead ribozyme by delivery through PEl mediated 
aerosolized therapy. This reduction was found to effectively decrease the 
multiplicity of B[a]P induced tumors in the murine lung. This reduction did not 
affect the size or types of tumors induced suggesting that pure inhibition of 
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cancer formation at the initiation step was attained and not just a progressive 
delay. These studies support the use of targeting TLS as a chemoprotective 
measure. The question remains as to why inhibiting certain TLS polymerase has 
such a diverse impact on cancer formation as shown by the end result of cancer 
formation. 
The provocative question regarding TLS implications in cancer is 
highlighted by comparisons between the end cancer results of Chapter II and III. 
In Chapter II the tumors appeared faster with TLS polymerase inhibition but TLS 
polymerase inhibition in Chapter III reduced tumor formation. The differences 
between these studies are supportive evidence that for a true decrease in cancer 
formation to occur TLS may have to be inhibited completely. If TLS is completely 
inhibited, cells are forced to resolve blocked DNA replication forks either by error-
free recombination or to undergo apoptosis. If TLS inhibition occurs at only the 
level of the specific polymerases responsible for bypass other polymerases may 
assume the bypass. This bypass could occur in either an error-prone or error-
free manner presumably dependent on both the type of lesion and specific 
polymerase performing the bypass. This mUlti-polymerase bypass is supported in 
Chapter" with pol iota assuming a larger role on both the leading and lagging 
strands in the absence of pol eta. Additionally, because there were residual 
mutations in the double knockouts, at least one other polymerase is capable of 
lesion bypass. This indicates TLS in Chapter II was not stopped but was rather 
merely altered. In contrast, REV1 inhibition appears to reduce the incidence of 
cancer. REV1 function in TLS is not considered to be catalytic, rather may be 
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structural acting to tether all of the polymerases that actually perform the bypass. 
Thus, REV1 inhibition abolishes TLS complex formation and drastically reduces 
the ability of cells to insert nucleotides across from lesions through TLS. With 
TLS completely shut down the logical system to assume function would be 
damage avoidance pathways. This pathway would appear to assume the role of 
TLS in an error free manner using undamaged templates to replicate the DNA. 
These data suggest that the most clinically useful approach in chemoprevention 
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